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ABSTRACT 
Newborn screening is a public health program that identifies newborns who are at risk of 
having a life-threatening condition that will affect their health in infancy or childhood. Fabry 
disease is an X-linked lysosomal storage disorder with a variable age of onset from childhood 
through adulthood that was recently added to a few states’ newborn screening panels. Research 
on patient attitudes towards newborn screening for Fabry disease has been limited and this 
qualitative study aimed to gain a more complete understanding of the reasoning of adults with 
Fabry disease regarding the appropriateness of newborn screening for Fabry disease, their 
knowledge of newborn screening, and their experiences with Fabry disease. Participants were 
recruited from Children’s Hospital of Pittsburgh of UPMC’s Lysosomal Storage Disorders Clinic 
and six adults who have Fabry disease were interviewed. These interviews were transcribed and 
thematic analysis revealed six themes:  influences of clinical spectrum and severity of Fabry 
disease, support systems, family dynamics, impact of timing of diagnosis and treatment 
availability on attitudes towards newborn screening, knowledge and attitudes towards newborn 
screening for Fabry disease, and impact of earlier diagnosis. Based on their personal experiences 
with Fabry disease, all participants were in favor of newborn screening for Fabry disease. 
Participants’ experiences with Fabry disease also reflected aspects of their family dynamics. The  
results of this qualitative study can inform genetic counseling practice for Fabry disease and 
future studies on NBS for Fabry disease. The opinions of stakeholders, including patients 
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affected by the condition, are of public health significance and the results of this study can 
inform public health decisions as state legislators and state newborn screening programs consider 
whether to include Fabry disease on their state’s newborn screening panel. 
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1.0  INTRODUCTION 
Newborn screening (NBS) is a public health program that identifies newborns who are at 
risk of having a life-threatening condition that will affect their health in infancy or childhood1. 
For newborns diagnosed with a life-threatening condition by confirmatory testing following 
NBS, a treatment or management plan is immediately created. Each state decides which 
conditions to include on its NBS panel1,2. When making decisions about additions to the NBS 
panel, the state considers recommendations from the federal government’s Advisory Committee 
on Heritable Disorders in Newborns and Children and the requests of parent activists and 
organizations3,4.  
One condition that was recently added to a few states’ NBS panels is Fabry disease, an 
X-linked lysosomal storage disorder. Fabry disease is caused by mutations in the GLA gene, 
which result in a deficiency of the lysosomal enzyme -galactosidase A (-Gal A) and the 
accumulation of globotriaosylceramide (GL3) in the lysosomes of cells throughout the body5,6. It 
is a progressive disorder and the clinical features of Fabry disease include neuropathic pain, 
progressive renal disease, cardiomyopathy, gastrointestinal (GI) symptoms, heat and cold 
intolerance, stroke, hypohidrosis, angiokeratomas, and corneal opacity7–12. Both hemizygous 
males and heterozygous females vary in which features they manifest and in the level of disease 
severity7,13,14. Compared to most conditions on NBS panels that have onset in infancy, the age of 
onset for Fabry disease is later, varying between childhood and adulthood, and treatment is 
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typically not recommended until there is an appearance of symptoms15–18. However, there is 
ongoing debate regarding which symptoms and signs to consider in this decision making and 
how to identify the earliest disease manifestations for both males and females15–18. The treatment 
for Fabry disease includes enzyme replacement therapy and management of symptoms17. 
Concerns have been raised among healthcare providers and experts about the appropriateness of 
screening for this condition due to the lack of consensus and evidence for when to start treatment 
in asymptomatic individuals19–21.  
Qualitative and quantitative studies have explored opinions about NBS among parents in 
the general population and parents of children with conditions on NBS panels22–26. In the general 
population, there is support for NBS for early-onset conditions and conditions which have a 
treatment available22. Parents, for example, generally support NBS for MPS I and Pompe 
disease, two lysosomal storage disorders that have variable ages of onset, including severe early 
infantile presentations, and have recently been added to some states’ NBS panels23,24. Research 
on patient attitudes towards NBS for Fabry disease has been limited to two studies that asked 
adults with Fabry disease about the timing of their diagnosis and their opinions on how a 
diagnosis at birth by NBS would have impacted their life and health25,26. In these studies, 
participants, in general, supported NBS for Fabry disease.  
The goal of this qualitative study is to gain a more complete understanding of the 
perceptions of adults with Fabry disease and parents of a child with Fabry disease regarding the 
appropriateness of newborn screening for Fabry disease. The results of this study have the 
potential to provide state legislators and healthcare providers with insight into the value 
assessment of NBS for Fabry disease among those living with the disorder. For states that have 
started screening for Fabry disease or will begin screening in the near future, these results will 
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also provide NBS programs and healthcare providers with information on the type of resources 
and support parents may want when faced with a positive newborn screen for Fabry disease. 
1.1 RESEARCH QUESTIONS 
• What understanding do adults and parents of a child with Fabry disease have of newborn 
screening’s purpose and process? 
• How do adults who have Fabry disease and parents of a child with Fabry disease view 
newborn screening for Fabry disease? 
1.2 SPECIFIC AIMS 
Specific Aim 1:  To conduct semi-structured interviews with adults with Fabry disease and 
parents of a child with Fabry disease. 
Specific Aim 2:  To analyze the interviews via thematic analysis to describe: 
• What adults who have Fabry disease and parents of a child with Fabry disease understand 
about newborn screening’s purpose and process. 
• The attitudes of adults who have Fabry disease and parents of a child with Fabry disease 
on newborn screening for this condition. 
To achieve these specific aims, adults who have Fabry disease and parents of a child who has 
Fabry disease were identified and recruited from the Children’s Hospital of Pittsburgh of 
UPMC’s Lysosomal Storage Disorders Program with the aid of the clinic’s primary clinical 
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genetic counselor.  Semi-structured interviews were conducted by telephone with six 
participants who have Fabry disease, five of whom have at least one first degree relative who 
is also affected. These interviews were transcribed and analyzed via thematic analysis to 
describe the participants’ understanding of newborn screening and their attitudes towards 
newborn screening for Fabry disease. 
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2.0  LITERATURE REVIEW 
2.1 FABRY DISEASE 
Fabry disease is an X-linked lysosomal storage disease that affects multiple organ 
systems. The onset of Fabry disease ranges from childhood through adulthood and it affects both 
males and females. The terms “classic” and “late-onset” are used to describe Fabry disease 
phenotypes, but as more is learned about the disease, these two terms do not adequately capture 
the wide spectrum and heterogeneity of the disease10. The classic phenotype tends to refer to 
individuals who experience multiple symptoms of Fabry disease with onset in childhood or early 
adulthood and the late-onset phenotype tends to refer to phenotypes which involve only one 
organ system and have onset in adulthood10,13,27. Fabry disease is a panethnic condition, meaning 
it is present in all races and ethnicities5. Before newborn screening was initiated in several 
countries and several US states for Fabry disease, the incidence of this condition was thought to 
be between 1 in 60,000 and 1 in 40,000 males28. The numbers from various states’ and countries’ 
newborn screening studies, which are described in the newborn screening section, indicate the 
incidence of Fabry disease ranges between 1 in 3859 and 1 in 287529,30. 
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2.1.1 Clinical Course 
2.1.1.1 Clinical Features 
Fabry disease is a vascular disease that affects multiple body systems, including the 
cardiac, renal, gastrointestinal, and nervous systems10,15. The condition also includes skin and 
eye changes, which are pathognomonic features of Fabry disease9,10. 
Cardiac features of Fabry disease include structural and conduction abnormalities in the 
heart11,31. The structural changes include mitral and aortic valve changes and progressive 
cardiomyopathy11,31. The typical presentation of cardiomyopathy in Fabry disease is left 
ventricular hypertrophy11. Conduction abnormalities in Fabry disease increase the susceptibility 
to arrhythmias31. Both males and females can develop cardiac symptoms, but males tend to 
develop these symptoms 10 years earlier than females31,32. The median age for males to develop 
cardiac symptoms is 43.5 years versus 54.9 years in females32.  
Individuals with Fabry disease are also at increased risk of cerebrovascular events, such 
as hemorrhagic strokes and transient ischemic attacks33. In a natural history study with 2,446 
individuals from the global Fabry Registry, approximately 6.9% of males and 4.3% of females 
with Fabry disease experienced a cerebrovascular event at a mean age of 39 years for males and 
45.7 years for females33. While the proportion of individuals who have cerebrovascular events is 
lower than those who experience cardiac or renal complications, 50% of males and 38.3% of 
females who have a stroke experienced their first stroke prior to being diagnosed with Fabry 
disease33.   
In the nervous system, the main feature of Fabry disease is acroparasthesia7. 
Acroparasthesias refer to neuropathic pain that starts in the palms of the hands and the soles of 
the feet; the pain may spread proximally to the joints and to the abdomen7. Individuals with 
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acroparasthesias have varying levels of burning and tingling, with similar mean age of onset in 
childhood and similar phenotype in both males and females7,34. Other nervous system features of 
Fabry disease are dizziness, tinnitus, hearing loss, and white matter hyperintensity in the brain35. 
The cause of white matter hyperintensities in the brain appears to be related to cerebrovascular 
disease and increases with disease progression, aging, and stroke35,36. 
There are also cognitive and psychological features in Fabry disease37,38. Individuals with 
more white matter lesions unrelated to stroke or compromised cerebrovascular integrity have 
slightly more cognitive, learning, and memory deficits than controls 37,38. Studies ranging in size 
from 17 to 25 individuals with Fabry disease from Germany and Australia suggest males have a 
slower speed of information processing and reduced performance on measures of executive 
function than controls37,38. Other studies have not seen the same cognitive findings38,39. There is 
also a higher prevalence of psychological distress such as anxiety, depression, and decreased 
social-adaptive functioning in individuals with Fabry disease38–40. The rate of depression in these 
studies ranged from 48% to 60%37,41. Researchers speculate that the higher frequency of 
depression is related to the burden of having a chronic multi-organ hereditary disease and not to 
the structural brain changes37. Research has found that depression rates are similar among 
individuals with varying amounts of white matter lesions37.  
The renal system is also affected by the accumulation of GL3 evidenced by progressive 
kidney disease42,43. The damage to the kidneys begins in childhood, but the symptoms of 
progressive kidney disease typically do not present until adulthood42,43. These symptoms include 
proteinuria, hypertension, increased serum creatinine, and reduced glomerular filtration rate42. 
Although there may be minimal symptoms present during childhood, there are significant 
pathological changes detectable by kidney biopsy in young males and females such as 
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glomerular and vascular changes and significanct GL3 accumulation44,45. In males, these 
symptoms present at a median age of 20 years and in females, at a median age of 28 years15.  
Gastrointestinal (GI) symptoms in Fabry disease include irritable bowel syndrome, 
unspecified functional bowel disorder, abdominal pain, diarrhea and functional bloating12,46. The 
onset of GI symptoms is in childhood, with 49.3% of children experiencing abdominal pain and 
25.4% with diarrhea12. Across all age groups, approximately 52% of individuals with Fabry 
disease experience GI symptoms and the most common symptoms are abdominal pain and 
diarrhea12. While other features of Fabry disease have a similar prevalence in both genders or a 
higher prevalence in males, 54.2% of females reported GI symptoms compared to 48.9% of 
males12. This difference between the genders for GI symptoms is also seen in the general 
population12. 
In addition to the major organ involvement described above, the hallmark features of 
Fabry disease include eye and skin findings and changes related to the autonomic nervous system 
such as temperature regulation and lack of sweating8–10. Approximately 50% of males and 
females have cornea verticillata, which are whorl-like opacities in the cornea that do not affect 
vision9. Less common eye findings are tortuous vessels and cataracts9. The hallmark skin finding 
in Fabry disease are angiokeratomas, which are benign small raised dark red spots that increase 
in number and size with age10. Individuals with Fabry disease can have hypohidrosis and heat 
and cold intolerance8. 
2.1.1.2 Age of Onset 
The age of onset of Fabry-related symptoms varies between males and females and also 
varies by phenotype. Data from the first 1765 individuals with Fabry disease in the Fabry 
Registry showed that the mean age of onset for males is 9 years and for females is 13 years15. 
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Males with the classical phenotype can present with symptoms as early as 2 years8. For 
individuals with an atypical or later-onset phenotype, symptoms related to the renal, cardiac or 
cerebrovascular symptoms have an onset in middle age13,16,27. Males and females experience a 
diagnostic lag after the onset of symptoms7,15. The average age at diagnosis for a male is 23 years 
and for females it is 32 years7,15. 
2.1.1.3 Inheritance and Recurrence Risk 
Fabry disease is inherited in a X-linked pattern47. Both males and females who have a 
pathogenic variant in the GLA gene exhibit features of Fabry disease10,14. There is a wider range 
of disease severity in females believed to be due in part to random X chromosome 
inactivation10,11,27. For males with Fabry disease, there is a 100% chance their daughters will 
inherit the GLA pathogenic variant and a 0% chance of their sons will inherit the GLA pathogenic 
variant. For females with Fabry disease, each of child (son or daughter) has a 50% chance of 
inheriting the GLA pathogenic variant5. 
2.1.1.4 Females with Fabry Disease 
Females who carry one pathogenic variant in the GLA gene were previously thought to be 
asymptomatic carriers7. Various studies involving heterozygous females have shown that 
females are not just carriers, but they exhibit features of Fabry disease with a range of disease 
severity depending on random X-inactivation7,14,48,49. Up to 1% of heterozygous females have the 
same level of severity in their symptoms as males7. Compared to the general population, females 
with Fabry disease have a higher prevalence of heart palpitations (48% Fabry vs. 13%), joint 
pain (58% Fabry vs. 25%), fatigue (89% Fabry vs. 57%), GI symptoms (82% Fabry vs. 51%), 
dizziness (60% Fabry vs. 19%), and loss of libido (60% Fabry vs. 23%)48. Females with Fabry 
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disease also have neurological features, cardiac features, and renal features34. These features 
convey a significant disease burden and can impair quality of life14. Data from the Fabry 
Outcome Survey from a European registry for Fabry disease provide information on the natural 
history and the prevalence and onset of symptoms in females34. Approximately 77% had 
neuropathic pain with mean age of onset equal to 16 years34. Other symptoms (cardiac, renal, GI, 
angiokeratomas) were present in 40-60% of women with a mean age of onset in their 20s and 
30s34.   
2.1.2 Molecular and Biochemical Basis of Fabry Disease 
2.1.2.1 Molecular Genetics and Disease Mechanism 
Fabry disease is a X-linked lysosomal storage disease (LSD)47. The lysosome is a cellular 
organelle which is responsible for breaking down complex macromolecules and recycling 
cellular debris50. In LSDs, the deficiency in a specific lysosomal enzyme results in the 
accumulation of its substrate in lysosomes50. The resulting accumulation of the substrate in 
lysosomes leads to impaired cellular function and progressive tissue and organ damage50. 
Fabry disease is caused by mutations in the GLA gene, which is located on chromosome 
Xq22.16,47. The GLA gene makes the lysosomal enzyme -galactosidase A (-Gal A)47. In 
lysosomes, -Gal A breaks down the glycolipid globotriaosylceramide (GL3)51. In Fabry 
disease, the deficiency in -Gal A leads to the accumulation of GL3 in lysosomes in the cells of 
most organs51. Although the exact mechanism of the features of Fabry disease are still being 
studied, the progressive accumulation of GL3 in cells leads to some of the features, such as heart 
and kidney disease52–55. In the heart, myocytes grow larger from the accumulation of GL3 and 
this leads to hypertrophic cardiomyopathy53,55.   
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2.1.2.2 Genotype-Phenotype Correlations 
The genotype-phenotype correlations in Fabry disease are limited. More than 750 
pathogenic variants have been identified in the GLA gene, but most of these variants are private 
mutations and their correlations with phenotype have not been well studied13,56. Low enzyme 
activity does not clearly predict phenotype29. Functional variants have been identified in the GLA 
gene that lead to low enzyme activity and no apparent disease features29. A few pathogenic 
variants are associated with later-onset phenotypes of Fabry disease in which only one organ 
system is affected, like the heart, the kidneys, or the cerebrovascular system13,27,35. One, the 
IVS4+919G>A allele, is associated with cardiac symptoms in adulthood and abnormalities on 
brain MRI that are similar to the abnormalities seen in the classical phenotype27,35. Having one 
D313Y allele may be associated with mild clinical symptoms, but there is also evidence this 
allele may be a benign polymorphism13,57. Two variants, p.Arg118Cys and D313Y, have been 
identified as risk factors for cerebrovascular disease13,58,59.  
2.1.3 Diagnosis 
For individuals with features suspicious for Fabry disease, a family history of the 
disorder, or a positive newborn screen, Fabry disease is diagnosed either through enzymatic 
testing or through molecular genetic testing. In males, demonstration of -Gal A deficiency in a 
blood plasma or leukocyte sample is a definitive method of diagnosis10,60. In females, a blood 
sample may not determine if -Gal A is deficient due to random X inactivation61. Therefore, 
molecular genetic testing and the identification of a pathogenic variant in the GLA gene is 
required to confirm a diagnosis of Fabry disease in a female10. Molecular genetic testing 
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confirms the diagnosis in males and provides the genotype, which may help in determining 
anticipated disease severity17. 
Diagnostic testing can also be performed in the prenatal period when the familial 
mutation is known62. Prenatal diagnostic testing can be done through amniocentesis or CVS and 
the samples undergo molecular testing62. Since Fabry disease is highly variable in females due to 
random X inactivation, the use of prenatal testing to diagnose heterozygous females is 
controversial and is not routinely performed62. 
2.1.4 Management 
The management of individuals with a pathogenic variant in the GLA gene requires a 
multidisciplinary approach with a team that often includes a geneticist, genetic counselor, 
nephrologist, cardiologist, and neurologist17,18. This multidisciplinary team is involved in treating 
the condition and its features, as well as in providing surveillance for other Fabry-related features 
that can occur17,18. The treatment and management of Fabry disease begins after the appearance 
of symptoms in males and females of any age17. Asymptomatic individuals with an identified 
pathogenic variant in the GLA gene should be followed closely for the development of any 
symptoms so treatment can begin before any potentially irreversible damage is done to the 
organs17. Research is being done to find a reliable biomarker to monitor the progression of Fabry 
disease during the asymptomatic period63. One possible biomarker that has been identified to 
monitor disease progression is blood concentrations of globotriaosylsphingosine (LysoGb3), 
which is a deacylated form of GL363. The management of Fabry disease includes enzyme 
replacement therapy, investigational treatments, and the specific management of any individual 
symptoms17,18. 
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2.1.4.1 Enzyme Replacement Therapy 
Enzyme replacement therapy (ERT) is a medical treatment that replaces the enzyme that 
is deficient in the body via an intravenous infusion64. The goal of ERT is to substitute at least 
some amount of the deficient enzyme to reduce the accumulation of the enzyme’s substrate and 
the associated symptoms65. ERT for Fabry disease is agalsidase beta, which is sold as 
Fabrazyme by Genzyme Corporation in the United States66. Outside of the United States, 
ERT for Fabry disease is either Fabrazyme  or agalsidase alfa, which is sold as Replagal by 
Shire HGT, Inc.66,67. Agalsidase beta is a recombinant form of human -Gal A that has an 
identical amino acid sequence to the natural form66. ERT is typically given intravenously every 
two weeks at a dose of 1mg/kg body weight66. 
At the cellular level, agalsidase beta clears microvascular endothelial deposits of GL3 
from renal, cardiac, and skin cells53. Clinical studies demonstrated that in the long-term and at 
the whole-body level, agalsidase beta reduces the number of severe clinical events, like heart 
failure, stroke, or kidney failure66. The 10-year outcome study on agalsidase beta showed that 
81% of adult participants receiving this ERT remained free of severe clinical events66. 
Agalsidase beta does not appear to cross the blood-brain barrier and strokes still occur in 
individuals taking ERT66.   
Ideally, ERT should be started when symptoms appear or when significant changes in the 
organs are detected17. In the 10-year outcome study of the original adult participants who 
participated in the Fabrazyme clinical trials, there were better outcomes in those who started 
ERT with less disease progression, especially related to progressive kidney disease66. Starting 
ERT after the progressive kidney disease has begun may not halt the progression or reverse the 
damage that has already occurred42. Although there were more severe clinical events in older 
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individuals and individuals with more advanced kidney disease, ERT prolonged their life 
expectancy by reducing the number of severe cardiac events66. 
2.1.4.2 Oral Chaperone Therapy 
Oral chaperones are molecules that assist in folding enzymes and transporting enzymes to 
their proper location in the cell68. The goal of oral chaperone therapies is to increase enzymatic 
activity by assisting the affected enzyme in its folding and transportation68. Oral chaperone 
therapies only work to treat the genetic condition if the affected enzyme still has catalytic 
competency, i.e. the affected enzyme must still be able to bind and process its substrate6. 
Migalastat by Amicus Therapeutics, Inc. is an oral chaperone therapy that is currently being 
studied to treat Fabry disease6,69. The chaperone works by binding and stabilizing -Gal A6. It 
then facilitates transporting -Gal A to lysosomes where the chaperone also increases the 
enzyme’s ability to break down GL36. Individuals need an amenable mutation that lead to a 
protein that expresses -Gal A with catalytic competence for Migalastat to work6,69.  
2.1.4.3 Guidelines for Management of Fabry disease 
General guidelines for the screening and management of Fabry disease have been 
published by Eng et al. and guidelines specific to the pediatric population have been published 
by Hopkin et al.17,18. At the initial evaluation, baseline assessments of the heart, kidneys, nervous 
system, eyes, ears, GI, skeleton for bone mineral density, and the general quality of life and 
psychological state are recommended17,18. After the comprehensive baseline assessment, each 
organ system should be regularly assessed17,18. Hopkin et al. recommend yearly evaluations, as 
well as regular monitoring by specialists for the heart, kidneys, and nervous system17. The 
pediatric guidelines and the American College of Medical Genetics and Genomics (ACMG) 
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Work Group on Diagnostic Confirmation of LSDs recommend that newborns be followed 
closely by a medical team experienced with Fabry disease every 6 months17,70. A more specific 
timeline for monitoring and treatment has not been defined for newborns due to a lack of 
evidence17. 
In general, a multidisciplinary medical team manages ERT and treats and follows 
symptoms of Fabry disease. The treatment of symptoms for Fabry disease may include analgesic 
drugs for pain relief, medications for GI motility, antiarrhythmic drugs for conduction 
abnormalities in the heart, and dialysis or renal transplantation for end-stage renal failure18. 
Based on current research, no medication are contraindicated in Fabry disease17,18. 
2.1.5 Psychosocial Concerns in Fabry Disease 
2.1.5.1 Quality of Life 
A number of studies with sample sizes ranging from 10 to 98 individuals have been done 
to assess the impact of Fabry disease on patient quality of life7,14,49,71–75. These studies have 
found that the features of Fabry disease affect the quality of life in multiple areas. Health-related 
quality of life (HRQoL) was assessed by looking at eight domains: physical functioning, role 
limitations due to physical health, role limitations due to emotional problems, energy/fatigue, 
emotional well-being, social functioning, pain, and general health72–74. Males and females had 
decreased HRQoL across all eight domains73,74.  
The contributors to quality of life varied slightly between males and females. Both males 
and females mentioned how pain, fatigue, and GI symptoms affected their quality of life49,71. 
Males perceived pain and hypohidrosis as most affecting their quality of life, whereas females 
perceived fatigue, exercise intolerance, and poor self-perception of health as most important to 
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their quality of life14,73. Fabry disease also affected school attendance, participation in sports, 
employment, and attending social activities in both males and females49,71. The quality of life 
improved significantly in individuals with Fabry disease after initiating ERT and this 
improvement was maintained 2 years after initiation72.  
Fabry disease-related pain is a large contributor to the quality of life7,49,71–73,76. Fabry 
disease-related pain negatively impacts multiple domains of life:  occupational functioning, 
relationship functioning, physical functioning, and emotional functioning76. With these domains, 
the pain affects individuals’ capacity to complete everyday physical tasks, like holding their 
child or loved one7,76. ERT seems to improve pain, but not significantly72.  
2.1.5.2 Other Effects of a Diagnosis and Disease Features 
The features of Fabry disease and being diagnosed with Fabry disease affect individuals’ 
perceptions of themselves and their mental health49,71,75,76. Angiokeratomas in the genital region 
led to embarrassment and decreased self-esteem in males with Fabry disease71. There is a higher 
rate of depression and anxiety in individuals with Fabry disease compared to 4.7% of the general 
population37,38,77. One study reported that 46% of individuals with Fabry disease had depression, 
of whom 28% were considered to have severe clinical depression41. The increased prevalence of 
depression seems to be at least partially related to having a chronic multi-organ hereditary 
disease and there is an association between disease severity and depression in those with Fabry 
disease37,41.   
2.1.5.3 Females with Fabry Disease 
Females with Fabry disease have the same psychosocial concerns as males because of the 
diagnosis and disease symptoms, but they face additional concerns because they are females14,76. 
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Heterozygous females were originally called asymptomatic carriers14. This label has contributed 
to females’ additional psychosocial concerns because females were dismissed as being just 
carriers14,76. Heterozygous females were referred to as asymptomatic carriers as recently as 2001 
and when a female had symptoms, the symptoms were considered mild49. A 2001 study on the 
clinical manifestations and impact of the disease in 60 obligate carrier females was one of the 
first studies that revealed that 30% of carriers had multiple symptoms and serious manifestations 
of Fabry disease49. In addition to previously being labeled asymptomatic carriers, symptomatic 
females with Fabry disease experience a diagnostic lag and are sometimes diagnosed as adults 
after a male relative or a younger female relative is diagnosed75,76. Gibas et al. noted being 
female is also a barrier to quality healthcare76. Thus, females with Fabry disease, a rare disease 
with non-specific symptoms, are hypothesized to be at a triple disadvantage to achieving quality 
healthcare76.  
A qualitative study on the experiences of being a heterozygous female with Fabry disease 
identified other factors apart from disease features that contribute to their psychosocial 
concerns75. Receiving the diagnosis caused concerns. Individuals who were diagnosed before 
symptoms developed had difficulty accepting the diagnosis75. For those who experienced 
symptoms prior to diagnosis, there was relief because the diagnosis provided a name for their 
symptoms75. The diagnosis led to a major change in how the women viewed themselves and how 
others, including healthcare providers, viewed them and their symptoms75. Prior to diagnosis, 
females in this qualitative study and other studies described healthcare providers as dismissive of 
their symptoms75,76. After being diagnosed, females were frustrated by their healthcare 
providers’ lack of general knowledge about Fabry disease75,76.   
 18 
2.2 NEWBORN SCREENING 
Newborn screening (NBS) is a public health program that identifies newborns who have 
an increased risk of having a life-threatening condition that will affect their health in infancy or 
childhood1. For newborns diagnosed with a life-threatening condition by confirmatory testing 
following NBS, a treatment or management plan is immediately created. 
NBS is not just a public health program, it is a public health system that is continuously 
being assessed for quality and timeliness. Changes to the system are made based on these 
assessments and on the public’s involvement. The assessment and change of the NBS system 
also includes a process for the addition of conditions to NBS panels.  
2.2.1 History 
NBS was made possible because of Dr. Robert Guthrie’s work with phenylketonuria 
(PKU). In 1961, Dr. Guthrie published a method of screening for PKU that involved measuring 
phenylalanine levels in heel-stick blood samples dried on filter paper78. This method made it 
possible to screen for PKU at the population level because of the ease of collecting the blood 
sample on filter paper that was stable enough to be mailed to a central testing laboratory79.  
NBS expanded from PKU to include more conditions over the next several decades as 
researchers and laboratorians found methods to screen for more conditions using the dried 
bloodspot. Some of the early additions to NBS included congenital hypothyroidism, 
hemoglobinopathies, biotinidase deficiency, and cystic fibrosis80–83. The number of conditions 
that NBS screened for increased dramatically in the 1990s with the implementation of tandem 
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mass spectrometry84. Tandem mass spectrometry made it possible to use a single test and a dried 
bloodspot to screen for multiple biochemical disorders85.  
2.2.2 Purpose 
NBS screens all newborns in a cost-effective manner to identify asymptomatic newborns 
who are at increased risk of having a life-threatening disorder or a disorder with long-term 
morbidities1,86. For infants identified to have one of these disorders in the newborn period 
through confirmatory testing, treatment and management can begin before the development of 
life-threatening symptoms or morbidities.  
NBS’s purpose and the conditions in NBS have been shaped by the Wilson and Jungner 
Criteria for screening19,87. Wilson and Jungner designed criteria to assess whether public health 
screening is appropriate for a specific condition87. These ten criteria were modified to assess 
conditions being considered for NBS19,88. Wilson and Jungner’s ten criteria are described in 
Table 187.  
Table 1. Wilson and Jungner Criteria 
1) Condition is an important health problem 
2) Treatment is available for the condition 
3) Facilities are available for diagnosis and treatment  
4) Condition has a presymptomatic or early symptomatic stage 
5) A test or exam exists to screen for the condition 
6) Population finds screening test acceptable 
7) There is an adequate understanding of the condition’s natural history 
8) There is a policy on whom to treat as patients 
9) The cost of positive screens, diagnostic testing and treatment of diagnosed individuals 
should be cost-effective 
10)  Screening for the conditions should be a continuing process 
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Wilson and Jungner’s criteria are still considered as conditions are added to NBS panels. These 
criteria have shaped the process by which conditions are approved for inclusion on NBS panels, 
including the Recommended Uniform Screening Panel, which is described in section 2.2.3.189 .     
2.2.3 Addition of Conditions to Newborn Screening Panels 
In the United States, NBS programs are operated at the state level2. Each state decides 
which conditions to include on its NBS panel1. Because of this, there was considerable 
variability in the conditions on NBS panels between states prior to 20062. State legislatures 
consider recommendations from the federal government and requests from their constituents in 
composing their state’s NBS panel, as well as budgets, resource availability, and technology. 
2.2.3.1 Recommended Uniform Screening Panel 
In 2002, the Department of Health and Human Services (HHS) wanted to make NBS 
programs more uniform across states89. To accomplish this goal, the US Secretary of the 
Department of HHS contracted with the American College of Medical Genetics to create the 
Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)3,89. The 
committee consisted of an expert panel that was tasked with informing the Secretary of HHS 
with evidence-based recommendations of conditions to include on NBS3,89. The committee’s 
work resulted in the Recommended Uniform Screening Panel or RUSP89. The initial RUSP was 
proposed by ACHDNC to the Secretary of HHS in 2006 and the Secretary endorsed the RUSP in 
20103. The panel originally included 29 core conditions and 25 secondary conditions89. 
The RUSP was proposed by ACHDNC and endorsed by the Secretary of HHS to provide 
states with guidance on which conditions to include in their NBS programs3. For newly 
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nominated conditions to be added to the RUSP, ACHDNC uses specific criteria in their rigorous, 
evidence-based assessment of a condition3. The Committee, in part, considers the benefits and 
harms in screening for the condition, the efficacy of the screening test, and how medical 
management would change if diagnosed through NBS2,3. Under medical management, ACHDNC 
evaluates whether the condition has an established therapeutic approach, including a specific 
treatment2,3. In 2013, ACHDNC revised these criteria to also include an evaluation of whether it 
is feasible, in part from workforce and fiscal perspectives, with each added new condition for the 
NBS and healthcare systems to screen for and follow up positive screens in the short-term and in 
the long-term3. 
Multiple LSDs have been nominated to the ACHDNC for inclusion on the RUSP: Pompe 
disease, mucopolysaccharidosis type I (MPS I), Krabbe disease, Niemann-Pick disease types 
A/B and Fabry disease4,16,90. Pompe disease was approved for inclusion in March of 2015 and 
MPS I was approved for inclusion in February of 20164,16. Fabry disease was proposed for 
inclusion in 2008 and the preliminary ACHDNC review recommended to not move to a full 
evidence review due to major gaps in data for review16. These included uncertainties in test 
sensitivity, lack of prospective NBS and treatment studies, and the relative prevalence of late-
onset disease variants16.  
2.2.3.2 Other Methods of Adding Conditions to Newborn Screening Panels 
Along with the recommendations from ACHDNC via the RUSP, states also consider 
adding conditions to their NBS panels that are proposed by parents and advocacy groups who 
lobby at the state level for the addition of a specific condition to their state’s NBS panel91. X-
linked adrenoleukodystrophy, a genetic disorder that primarily affects the nervous system, was 
added through this method to the New York and Connecticut NBS panels92. Through this 
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method, screening for Krabbe disease, another LSD, was implemented in New York in 200691. In 
Illinois, parents successfully lobbied their legislature to mandate screening for five LSDs, 
including Fabry disease91. 
2.2.4 Newborn Screening Process 
In the United States, NBS programs are operated by the states2. All states in the United 
States have a law that mandates or offers NBS93. Each state program decides the details of how 
to screen newborns and how to follow-up with any positive screens, but the general process is 
similar across all states. A blood sample is collected via heel stick on to filter paper from the 
newborn no later than 48 hours of life1. Filter papers are sent to the state’s NBS laboratory or the 
commercial laboratory that has been contracted by the state93.  
The steps following a positive newborn screen vary by state and by condition. For some 
conditions, a positive screen is followed by reflexing to a more specific test that measures 
additional analytes or sequences DNA for common pathogenic variants1. This step reduces false 
positive rates and aids in the diagnostic process following a positive screen. Some conditions that 
NBS screens for are considered time-sensitive and are conditions in which treatment must begin 
immediately1,94. When there is a positive screen for one of these time-sensitive conditions, the 
NBS lab must contact the specialist or the primary care provider within 5 days of birth with the 
results94. The follow-up procedures for positive screens for conditions that are not time-sensitive 
varies slightly state by state. In general, positive NBS results are communicated by the NBS 
laboratory to the physician listed on the newborn’s NBS bloodspot card and to the specialty 
clinic. The physician then relays these results to the newborn’s parents. In all cases, a positive 
newborn screen is followed by an appointment with a specialist and confirmatory diagnostic 
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testing to confirm or rule out the diagnosis1. A treatment or management plan is created for 
newborns with a confirmed diagnosis.  
As a public health system, NBS in the United States not only involves the process of 
testing dried bloodspots and following positive screens, but it also involves continuously 
assessing and improving the NBS system. At the national level, different programs are 
responsible for quality assurance, assessment, and implementing research into NBS practice86. 
The Newborn Screening Quality Assurance Program (NSQAP) at the Centers for Disease 
Control and Prevention helps NBS laboratories with providing high quality testing, minimizing 
false-positives and improving the process to ensure testing does not delay a newborn’s 
diagnosis86. Another resource available to NBS laboratories, researchers, and healthcare 
providers is the Newborn Screening Translational Research Network (NBSTRN). One major 
initiative of Mayo Medical Laboratories and NBSTRN is the Region 4 Stork Collaborative 
Project (R4S), which developed a system to interpret analyte ratios to improve the screening 
predictability for metabolic disorders involving amino acids and acylcarnitines, primarily to 
reduce false positive screens16. This project has expanded to include LSDs and some of the pilot 
studies on NBS for LSDs are sharing their data with R4S16,95. The R4S project evolved to 
become the Collaborative Laboratory Integrated Reports (CLIR), which collects data on true 
positives from across the world, includes more conditions, and can be used outside of NBS96. 
2.2.5 Newborn Screening for Fabry Disease and Other Lysosomal Storage Disorders 
A number of research groups, states, and countries have studied various components of 
NBS for Fabry disease and other LSDs:  the method of screening, feasibility of NBS for Fabry 
disease, and the short-term and long-term implications of NBS for Fabry disease29,30,97–105. 
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2.2.5.1 Newborn Screening Methods for Fabry Disease and Other Lysosomal Storage 
Disorders 
Two main methods have been developed to screen for Fabry disease from a NBS dried 
bloodspot: the fluorometric method and tandem mass spectrometry50,97,98,106–108. Both methods 
measure enzymatic activity50,97,108. The fluorometric method uses an artificial fluorescent 
substrate and tandem mass spectrometry uses a substrate that is closer to the natural 
substrate50,107,108. A modified version of the fluorometric method is used in digital microfluidics, 
which measures enzyme activity on a microchip50,106.    
Most pilot studies and NBS programs use tandem mass spectrometry to screen for Fabry 
disease and other LSDs97,100,101. Comparisons between different research and pilot studies that 
used tandem mass spectrometry or digital microfluidics revealed that tandem mass spectrometry 
is better at differentiating between affected and unaffected individuals, resulting in fewer false 
positive newborn screens106. Multiple research groups have worked on a method to screen for 
multiple lysosomal enzymes in a single multiplex assay with tandem mass spectrometry97,98. This 
approach provides an internal control that minimizes the number of false positives97. If more 
than one lysosomal enzyme is low, it is a clue that there may be an error in the assay and the 
newborn may not have that LSD97,99.  
While tandem mass spectrometry has proven to be accurate in detecting newborns with a 
LSD, its ability to detect newborn females with Fabry disease has limitations. Because Fabry 
disease is a X-linked condition, heterozygous females have a wide range of -Gal A activity in 
their blood cells due to random X inactivation97. Females with low -Gal A activity in their 
blood cells will screen positive with this method, but it will primarily detect hemizygous males 
who have low or no -Gal A activity61,97.  
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2.2.5.2 In the United States 
A few states in the United States have passed legislation that instituted screening for 
Fabry disease and other LSDs through NBS. Missouri, Illinois, and New York citizens have 
passed legislation and programs have begun screening for Fabry disease and other LSDs either at 
the population level or in pilot studies99–101. New Jersey, New Mexico, and Pennsylvania have 
legislation to screen for Fabry disease and other LSDs, but screening has not yet been 
implemented for Fabry disease109,110. 
Missouri was the first state to perform a full population pilot study starting in January of 
2013 on four LSDs:  Fabry disease, Pompe disease, Gaucher disease and MPS I99,111. The entire 
NBS process for LSDs from testing dried bloodspots to follow-up referrals to genetics centers 
was investigated99. This state also started a full population pilot study on NBS for Krabbe disease 
in August of 2012111. Unlike other NBS programs that used tandem mass spectrometry for their 
testing, the Missouri program uses the digital microfluidic method to screen for these four LSDs 
and Krabbe disease99. For Fabry disease, there were 89 newborns, both males and females, with 
positive screens112,113. Of these newborns, 40 were confirmed to have Fabry disease because of 
low enzyme levels and genetic testing112. Genotype data showed that one newborn has the classic 
form, 35 newborns have late-onset, and four newborns have variants of uncertain significance112. 
Based on these numbers, the incidence of Fabry disease in Missouri is about 1 in 2875 people112. 
Through this population pilot study, Missouri found a high prevalence of the A143T allele, seen 
in 26 of the 40 diagnosed newborns112. The Missouri NBS program thought further research was 
needed to clarify whether the A143T allele is a pathogenic variant or if it is a pseudodeficiency 
allele112. Lenders et al. studied this allele further and classified it as a most likely a neutral 
variant or a possible modifier114. They found that males with this genotype still have significant 
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residual enzyme activity, less severe symptoms, and no renal or cardiac involvement114. The 
pathogenicity of the A143T allele is still an area of ongoing debate and research115. 
Illinois began a pilot study to screen for five LSDs (Pompe disease, Fabry disease, 
Gaucher disease, MPS I, and Niemann Pick disease types A and B) using tandem mass 
spectrometry in November of 2014100. The pilot study transitioned to statewide screening in June 
of 2015100.  By September of 2015, the state had screened 63,007 newborns for these five LSDs. 
Of these newborns, 40 screened positive for Fabry disease100. Four newborns, all males, were 
confirmed to have Fabry disease, 15 newborns had negative diagnostic testing, 19 newborns had 
pending results, one newborn’s family refused further testing, and one newborn passed away 
before further testing100. Genetic testing in the four boys with Fabry disease showed two boys 
have late-onset variants and two boys have genotypes with unknown phenotypes100. An 
investigation of the positive newborn screens for Fabry disease at Lurie Children’s Hospital in 
Chicago noted that many of the newborns with low -Gal A activity have previously unreported, 
novel mutations in the GLA gene that are predicted to be associated with late-onset Fabry 
disease116.  
New York passed legislation in 2006 and instituted screening for Krabbe disease, another 
LSD16. For other LSDs, New York is currently conducting a prospective consented pilot study in 
four New York City hospitals to investigate the clinical aspects of screening newborns for 
LSDs101. Between May of 2013 and September 1, 2016, 73% of approached parents consented to 
have their newborn screened for Fabry disease, Pompe disease, MPS I, Gaucher disease, and 
Niemann-Pick disease types A and B101. Using dried bloodspots and tandem mass spectrometry, 
49,996 newborns were screened for these LSDs101. For Fabry disease, 16 newborns screened 
positive. 15 of the 16 newborns were followed up with additional testing:  10 newborns had 
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later-onset genotypes, three newborns had negative genetic testing, and two newborns have 
results pending101. This pilot study has only detected later-onset genotypes for Fabry disease, 
which poses a challenge to the traditional purpose of NBS of identifying newborns at risk of 
developing symptoms in infancy or childhood101.    
2.2.5.3 Around the World 
Italy, Taiwan, Austria, Japan, Hungary, and Mexico have conducted pilot studies on NBS 
for Fabry disease29,30,102–105. These studies have found that the prevalence of Fabry disease is 
approximately 1 in 3000 people, which is much higher than the previously quoted prevalence of 
1 in 40,000 males28–30,102. The studies also found a high ratio of late-onset genotypes compared 
to classical genotypes30,102,103. These countries have not started screening newborns for Fabry 
disease. While their methods have proven effective in detecting newborns with variants in the 
GLA gene, most of these research groups have reservations about population-wide screening in 
newborns for multiple reasons. Their research has revealed a high prevalence of individuals with 
late-onset Fabry disease, a high prevalence of variants that are not well defined, and no clear 
guidelines on how to manage newborns diagnosed with a late-onset condition30,102,103,117. Italy’s 
research group suggested screening for Fabry disease in early adulthood given the high 
prevalence of late-onset variants102.  
2.2.6 Issues in NBS for Fabry Disease 
A number of stakeholders (NBS researchers, bioethicists, and genetics healthcare 
providers) have voiced their concerns about NBS for Fabry disease. Their issues and concerns 
with NBS for Fabry disease include whether NBS should be done for Fabry disease, how a 
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condition is added to NBS, issues with the screening test, concern over the availability of 
resources for follow-up, how asymptomatic children would be followed, and psychosocial and 
ethical concerns related to these issues. 
These stakeholders have questioned whether NBS Fabry disease should be screened as 
part of NBS because of a lack of understanding of the disease’s natural history and management. 
Additional concerns include the limited knowledge on genotype-phenotype correlations, limited 
natural history information on late-onset and atypical variants, and limited research on when 
treatment in asymptomatic individuals should begin19–21,118,119. Limited management guidelines 
exist for how to manage an asymptomatic individual with Fabry disease, which is particularly 
problematic for asymptomatic newborns diagnosed through NBS19,20,118,119. Some stakeholders 
are concerned with the screening test because it fails to detect 1/3 of heterozygous females with 
Fabry disease19,61. 
These stakeholders have additional concerns with the resources required for NBS for 
Fabry disease19–21,119. With the follow-up required for positive newborn screens, there is concern 
with the shortage of genetic healthcare providers and the small number of diagnostic laboratories 
that provide tests for LSDs20,21. The financial costs of additional tests, evaluations, and 
treatments to the family, the healthcare system, and the insurance system are also worrisome, 
particularly since guidelines for symptomatic individuals are being applied to manage 
asymptomatic newborns20,119. Others point out that the costs must be weighed between the 
management of an untreated individual with Fabry disease and the management of an 
asymptomatic diagnosed individual20. But cost-effectiveness studies on NBS for Fabry disease 
have not yet been completed to determine whether it is less costly to be diagnosed at birth20.   
 29 
Many of the concerns with testing, resources, and follow-up raise psychosocial concerns 
for families who receive a positive screen or diagnosis for Fabry disease for their newborn child. 
Families experience emotional distress between the time they receive a positive newborn screen 
and when results of diagnostic testing are available118. Since there are no clear genotype-
phenotype correlations, natural history information on some of the later-onset and atypical 
variants, or consensus on when to start treatment in asymptomatic individuals with Fabry 
disease, families are given ambiguous test results for their newborn child, which increases 
parental anxiety21. Parent advocates of NBS for LSDs have argued that avoiding the diagnostic 
odyssey is a benefit of NBS118. While NBS would avoid the psychological harms of a diagnostic 
odyssey, there is concern over the psychological harms of a “diagnosis-in-waiting”118. With a 
diagnosis at birth, parents may be over-protective of the child diagnosed with Fabry disease 
when there are no symptoms118.    
The ambiguous test results and high prevalence of later-onset variants raises ethical 
concerns with NBS for Fabry disease. The data from multiple pilot studies show that most Fabry 
disease variants are later-onset19. In the clinical setting, healthcare providers do not test children 
for adult-onset conditions to give children the autonomy to decide when they are adults whether 
they want testing19,21. Given the high prevalence of later-onset variants in Fabry disease, NBS for 
Fabry disease goes against the position of not testing children for adult-onset conditions19. 
Another ethical issue with NBS for Fabry disease is that NBS is done without informed parental 
consent19,119. Parents have the option to opt-out of NBS in some states, but that means parents 
decide about screening for all conditions on NBS or none of them120. 
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2.3 PARENTS’ ATTITUDES AND OPINIONS ON NEWBORN SCREENING 
Qualitative and quantitative studies have asked participants about their attitudes and 
opinions on NBS in general and on NBS for specific conditions. Some focus on attitudes of 
parents in the general population. Others have focused on parents of children with conditions 
being added to NBS panels and adults with these conditions and examine what they think of 
NBS for these conditions. 
2.3.1 General Population 
In the general population, parents are in support of NBS for conditions where an earlier 
diagnosis has clinical benefit22,121. Parents considered an established and effective treatment for 
the condition and an early-onset condition, especially one that might not be easily diagnosed, as 
the most important clinical benefits of NBS for the condition121. Many parents saw a benefit in 
NBS for an early-onset condition that does not have an established treatment to plan finances, 
care-giving needs, and reproductive decisions121. For later-onset conditions that had no clinical 
benefit from earlier diagnosis, many parents suggested waiting to screen for these conditions or 
to make these conditions optional121. Parents in the general population were more in support of 
NBS when an earlier diagnosis for affected newborns meant significant health improvements and 
were willing to tolerate the burdens of testing their unaffected newborns for these significant 
health improvements22. Parents who have a child seen by genetics healthcare providers supported 
a broader variety of conditions for inclusion on NBS than parents who do not have a child 
followed at a genetics clinic121. A few parents were concerned about the harms of screening 
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newborns for these conditions, including the harms to the diagnosed newborn and the harms to 
the family if NBS results in a false positive22,121. 
2.3.2 Specific Conditions 
2.3.2.1 MPS 
Mucopolysaccharidoses (MPS) are a group of LSDs that have variable ages of onset from 
infancy through adulthood23. MPS type I, was added to the RUSP in 20164. Hayes et al. surveyed 
adults with a MPS disorder and parents of a child who has a MPS disorder for their opinions on 
NBS for MPS disorders23. The participants’ level of support depended on the severity of the 
specific MPS and whether treatment was available23. 97% of participants were in support of NBS 
for MPS when an early treatment is available that has clinical benefit, 87% supported NBS for 
severe forms of MPS that have no treatment available, and 84% supported NBS for mild forms 
of MPS that have no treatment available23. The most common reason participants shared in 
support of NBS for MPS disorders is to avoid a delay in diagnosis and to avoid the distress that 
accompanies a delayed diagnosis23. As in the general population, a few participants mentioned 
concerns with diagnosing a newborn with MPS who otherwise looks healthy23,121.   
2.3.2.2 Duchenne/Becker Muscular Dystrophy and Spinal Muscular Atrophy 
Duchene muscular dystrophy, Becker muscular dystrophy, and spinal muscular atrophy 
are neuromuscular disorders that have an age of onset ranging early childhood to adulthood122. 
Wood et al. surveyed parents of children who have Duchenne or Becker muscular dystrophy, 
parents of children who have spinal muscular atrophy, and expectant parents from a prenatal 
clinic about their opinions on NBS for these three conditions122. Without further advancements in 
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treatment, 95.9% of parents with an affected child and 92.6% of expectant parents supported 
NBS for Duchenne and Becker muscular dystrophies and spinal muscular atrophy122.  
2.3.2.3 Pompe Disease 
Pompe disease is a LSD that has infantile and later-onset forms24. This condition was 
officially added to the RUSP in 201516. Before it was added to the RUSP, Weinreich et al. 
surveyed parents of a child with Pompe disease and a group of parents from the general 
population about their opinions on NBS for Pompe disease24. 87% of the group from the general 
population and 88% of parents of a child with Pompe disease supported NBS for Pompe 
disease24. Although there was equal support for NBS for Pompe disease from both groups, the 
parents of a child with Pompe disease expected a greater benefit from a newborn being 
diagnosed with later-onset Pompe disease than the group from the general population24. 
2.3.2.4 Fabry Disease 
The research on attitudes about NBS for Fabry disease has focused on asking adults with 
Fabry disease about the timing of their diagnosis and how their lives would have been impacted 
by a diagnosis at birth via NBS25,26.  
Bouwman et al. conducted a qualitative study on the timing of diagnosis in adults with 
Fabry disease25. Based on the results of this study, Bouwman et al. suggested the timing of 
diagnosis is a relevant aspect to consider when deciding about NBS for Fabry disease25. The 
researchers found some disparities in what participants were saying about the implications of an 
earlier diagnosis because of the differences in their experiences with Fabry disease. The 
participants with more severe symptoms felt misunderstood and were frequently misdiagnosed, 
whereas other participants felt the diagnosis led to labeling and medicalization25. While there 
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were differences in how participants viewed an earlier diagnosis, a common theme among the 
participants was that an earlier diagnosis would lead to timely initiation of treatment before the 
disease progresses25. 
Lisi et al. surveyed adults with Fabry disease and other later-onset LSDs about the timing 
of their diagnosis, their opinions on NBS for later-onset LSDs, and how a diagnosis at birth 
would have impacted them26. The timing of diagnosis varied considerably among the 47 Fabry 
participants26. Of the Fabry participants, 60.9% experienced a diagnostic lag of at least five 
years. The second largest subset of Fabry participants, 28.3%, were diagnosed before any 
symptoms appeared. In general, most participants supported NBS for these later-onset LSDs 
(Fabry disease, Gaucher disease, and Pompe disease) and recognized that a diagnosis via NBS 
could prevent irreversible damage. The survey also questioned participants about how a 
diagnosis at birth via NBS would have impacted their lives. Approximately half of the 
participants thought their health would be better and they would be more satisfied if diagnosed at 
birth. From the survey response choices provided, several participants said they would make 
different life decisions, including reproductive decisions. In the free-response section, a few 
participants elaborated on their survey responses. Some Fabry participants elaborated that being 
diagnosed earlier would have had a negative impact because they would have made more 
cautious life decisions. The free-response section also revealed that some Fabry participants felt 
differently about being diagnosed earlier based on the onset and severity of their symptoms. One 
participant who still did not have symptoms said an earlier diagnosis would not have changed his 
life. Another participant stated that if he had been diagnosed earlier, he would not be as 
handicapped and he could have worked and socialized more.  
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3.0  MANUSCRIPT 
3.1 BACKGROUND 
3.1.1 Fabry disease 
Fabry disease is an X-linked lysosomal storage disease (LSD)47,51. It is caused by 
mutations in the GLA gene, which leads to a deficiency in the enzyme -galactosidase A (-Gal 
A) and the accumulation of its substrate globotriaosylceramide (GL3) in cells throughout the 
body47,51. The features of Fabry disease include progressive cardiomyopathy, progressive renal 
disease, stroke, gastrointestinal symptoms, neuropathic pain, angiokeratomas, heat and cold 
intolerance, hypohidrosis, and corneal opacity7–12,15.  
The spectrum and severity of features varies among individuals and the age of onset 
ranges from childhood through adulthood7,13–15. The terms “classic” and “late-onset” are used to 
describe Fabry disease phenotypes, but as more is learned about the disease, these two terms do 
not adequately capture the wide spectrum of the disease10. The classic phenotype tends to refer to 
individuals who experience multiple symptoms with onset in childhood or early adulthood and 
the late-onset phenotype refers to phenotypes which involve only one organ system and have 
onset in adulthood10,13,27. Genotype-phenotype correlations are limited in Fabry disease because 
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most pathogenic variants are private mutations that have not been well studied13,56. A few 
pathogenic variants have been found to be associated with late-onset phenotypes13,27,35. 
3.1.1.1 Treatment and management of Fabry disease 
It is recommended that a multidisciplinary team manage treatment and monitoring of 
disease progression in affected patients18. Based on current guidelines, treatment begins after 
symptoms appear and asymptomatic individuals with Fabry disease are closely followed to 
monitor for the emergence of symptoms17,18. Research is being done to find a reliable biomarker 
to monitor the progression of disease during the asymptomatic period and one possible 
biomarker is globotriaosylsphingosine (LysoGb3)63. The treatment guidelines for Fabry disease 
do not have specific recommendations for asymptomatic patients with late-onset variants or 
asymptomatic newborns17. Treatment for Fabry disease includes management of individual 
symptoms, enzyme replacement therapy (ERT), and investigational treatments6,17,18. ERT for 
Fabry disease (Fabrazyme  by Genzyme Corporation  and Replagal by Shire HGT, Inc.) 
reduces the number of severe clinical events, such as heart and kidney failure, and prolongs life 
expectancy66,123. Better outcomes have been reported in individuals who started ERT with less 
disease progression66. ERT does not reverse the damage that has already occurred and it does not 
appear to cross the blood-brain barrier42,66. Migalastat, an oral chaperone that stabilizes and 
transports -Gal A to lysosomes, is being investigated as a possible treatment for individuals 
with variants of -Gal A that are able to bind and break down GL36. 
3.1.1.2 Psychosocial concerns in Fabry disease 
Some of the features of Fabry disease, particularly pain, negatively impact multiple 
domains of quality of life7,14,49,71,72,74,75. There is a higher rate of depression and anxiety in 
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individuals with Fabry disease compared to the general population, which may be partially 
associated with having a chronic hereditary disease37,38,41. Symptomatic individuals with Fabry 
disease have described healthcare providers as being dismissive of their symptoms and the 
diagnosis provided a name for their symptoms, which changed how they viewed themselves and 
how healthcare providers viewed them75,76.  Females with Fabry disease face additional 
psychosocial concerns because they were referred to as asymptomatic carriers as recently as 
200114,49,76.  
3.1.2 Newborn screening for Fabry disease 
Fabry disease was recently added to a few states’ newborn screening panels. Newborn 
screening (NBS) is a public health program that identifies newborns who are at risk of having a 
life-threatening condition that will affect their health in infancy or childhood1. For newborns 
diagnosed with a life-threatening condition by confirmatory testing following NBS, a treatment 
or management plan is immediately created. In the United States, each state decides which 
conditions to include on its NBS panel1,2. The Advisory Committee on Heritable Disorders in 
Newborns and Children (ACHDNC), a federal committee, makes recommendations to state NBS 
programs through the Recommended Uniform Screening Panel (RUSP)3,89. ACHDNC conducts 
an evidence-based assessment to see if a nominated condition meets specific criteria before 
recommending to the US Secretary of Health and Human Services that it be added to the RUSP3. 
Fabry disease was nominated for inclusion in 2008 and ACHDNC rejected the proposal without 
requesting an evidence review because of the prevalence of late-onset disease variants, 
uncertainties in test sensitivity, and the lack of prospective NBS and treatment studies16. Parents 
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and advocacy groups have lobbied at the state level for conditions to be added to the state’s NBS 
panel, which is how Fabry disease and four other LSDs were added to Illinois’s NBS panel4,91. 
Missouri, Illinois, New York, New Jersey, New Mexico, and Pennsylvania have passed 
legislation for Fabry disease to be added to the state’s NBS panel99–101,109,110. Missouri and 
Illinois are screening all newborns for Fabry disease and New York is currently conducting a 
prospective consented pilot study in four New York City hospitals99–101. Data from these pilot 
studies and screening programs revealed a higher prevalence of Fabry disease and a higher ratio 
of late-onset variants compared to classic variants than anticipated100,101,112,116. Pilot studies from 
other countries found similar results29,30,103–105,124. These studies and screening programs have 
found that the prevalence of Fabry disease is about 1 in 3000 people, which is higher than the 
previously quoted prevalence of 1 in 40,000 males28–30,112,124.   
3.1.3 Concerns with newborn screening for Fabry disease 
The results of these newborn screening programs’ and pilot studies’ as well as various 
stakeholders have raised multiple concerns with NBS for Fabry disease. Stakeholders have 
addressed the potential impact of NBS for Fabry disease on the small number of medical centers 
and genetics healthcare providers who treat LSDs and the financial costs of more tests, 
evaluations, and treatments19–21,119. These providers follow any newborn with a positive screen 
and the newborn’s family members who are subsequently diagnosed125. There are also concerns 
with the screening test since it does not detect 1/3 of heterozygous females with Fabry 
disease19,61. Limited information on genotype-phenotype correlations makes it difficult to 
categorize an asymptomatic newborn as classic or late-onset19–21,104,105,116,118. There is no 
consensus on when to start treatment and how to follow asymptomatic individuals because of the 
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limited number of studies on these topics19,20,118. Limited information on genotype-phenotype 
correlations and management makes it difficult for healthcare providers to create a management 
plan and to counsel families with a diagnosed newborn20,116. The high ratio of late-onset variants 
raises ethical concerns with testing children for an adult-onset condition19,21,101,124. For newborns 
diagnosed at birth and their families, research on families’ experiences with uncertain NBS 
results suggest the psychological harms of a “diagnosis-in-waiting” may outweigh the benefits of 
avoiding the diagnostic odyssey118,126. 
3.1.4 Parents’ and patient’s opinions on newborn screening 
As more conditions are added to NBS panels, quantitative and qualitative studies have 
explored individuals’ opinions on NBS. In the general population, parents are in support of NBS 
for conditions when an earlier diagnosis has clinical benefit22,121. Parents, for example, generally 
support NBS for MPS I and Pompe disease, two lysosomal storage disorders that have variable 
ages of onset, including severe early infantile forms, and have recently been added to some 
states’ NBS panels23,24. 
Analysis of opinions and attitudes on NBS for Fabry disease are limited to one qualitative 
study and one quantitative study25,26. The qualitative study explored the timing of diagnosis in 
adults with Fabry disease and found that participants generally supported an earlier diagnosis for 
earlier treatment initiation25. Participants with more severe symptoms felt misunderstood and 
were frequently misdiagnosed prior to diagnosis while other participants felt the diagnosis led to 
labeling and medicalization25. The quantitative study surveyed adults with Fabry disease and 
other late-onset LSDs (Gaucher disease and Pompe disease) to gain a more complete 
understanding of how a diagnosis at birth through NBS would have impacted them26. These 
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participants completed a survey about the timing of their diagnosis, their opinions on NBS for 
late-onset LSDs, and how a diagnosis at birth would have impacted them26. Most participants 
supported NBS for late-onset LSDs26. From the survey answer choices provided, about half of 
the participants who have Fabry disease indicated an earlier diagnosis would have led to better 
health, greater life satisfaction and different life decisions, including reproductive and financial 
decisions26. Out of 47 participants with Fabry disease, a few participants elaborated on their 
survey responses in the free-response section26. These responses revealed how a diagnosis at 
birth would have impacted their lives positively (“would not be as handicapped”) or negatively 
(“would not have pursued athletics as intensely and successfully as I did”).  
As conditions are added to NBS panels, it is important to understand the opinions of 
different stakeholders, including people who have been affected by the condition. Previous 
studies have explored the opinions of some NBS stakeholders, like healthcare providers, family 
members of patients, and the general public, but very few LSD patients have been included in 
NBS research thus far22–24,121,122. This qualitative study aimed to gain an understanding of the 
perceptions of adults with Fabry disease regarding the appropriateness of NBS for Fabry disease, 
the reasoning behind their opinions on NBS, and their knowledge of NBS. To accomplish these 
aims, semi-structured interviews were conducted with adults who have Fabry disease and these 
interviews were analyzed via thematic analysis.  
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3.2 METHODS 
3.2.1 Participants 
The target population for this study included adults (18 years or older) who have Fabry 
disease or adults who have a child who has Fabry disease. Participants were recruited from the 
Children’s Hospital of Pittsburgh of UPMC’s Lysosomal Storage Disorders Clinic. The primary 
clinical genetic counselor for the Lysosomal Storage Disorders Clinic identified potential 
participants from the clinic roster and sent an invitation letter to them on behalf of the study team 
(Appendix B). The genetic counselor provided the study team with potential participants’ names 
and contact information before the invitation letters were sent out for the purpose of tracking 
responses. The invitation letter introduced the lead researcher, the purpose of the study, and the 
format of the interview with participants. Enclosed with the invitation letter, potential 
participants were provided with a response card to indicate their interest in learning more about 
the study and to provide their contact information if they were interested. When potential 
participants indicated they were interested on the returned response card, the researcher called 
them to speak further about the study and to obtain informed consent through the verbal consent 
script (Appendix C). The verbal consent script covered the purpose of the study, format of the 
interview, the voluntary and confidential nature of the interview, how data would be stored 
securely, and contact information for the study and IRB office should they have any questions or 
concerns. The lead researcher also called potential participants who did not send back response 
cards a maximum of two times to inquire about their interest in learning more about the study, 
and obtained informed consent from those who were interested. Once consented to participate in 
the study, the participant was given the option to schedule a time for an in-person or phone 
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interview. Before the scheduled interview, participants were sent an educational brochure on the 
purpose and process of newborn screening in a sealed envelope with directions that it was to be 
opened during the interview. The educational brochure was created for this study and its 
information was tailored to newborn screening for Fabry disease (Appendix E). Federal and state 
government websites on newborn screening were referenced for the content of the brochure. 
Writing of the brochure was targeted to an 8th grade reading level; however, a 9th grade reading 
level was achieved. This was assessed through use of a readability calculator throughout its 
development. Six participants with Fabry disease, two males and four females, participated in the 
study. Participants were not provided with any financial compensation. 
An interview guide for the semi-structured interviews was created to explore participants’ 
experiences with Fabry disease and their opinions on newborn screening for Fabry disease 
(Appendix D). The guide was created by the lead researcher and supplemented and edited by 
three genetic counselors with experience in qualitative research and genetic counseling for 
lysosomal storage disorders. The first part of the interview guide asked open-ended questions 
about participants’ and their family’s experiences with Fabry disease, including how and when 
they were diagnosed, symptoms they have experienced, and how the diagnosis has impacted 
them and their families. The second part of the interview guide asked open-ended questions 
about participants’ opinions on newborn screening for Fabry disease, the type of counseling and 
support they would want with a diagnosis via newborn screening, and how a diagnosis at birth 
via newborn screening would have impacted them and their families. The study was reviewed 
and approved by the University of Pittsburgh IRB committee (Appendix A). 
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3.2.2 Data Collection 
Semi-structured interviews were conducted between December 2016 and March 2017. 
All six participants opted to have their interviews conducted over the phone. All interviews were 
conducted by the same researcher and lasted between 35 minutes and 1 hour. At the beginning of 
each interview, participants were reminded that participating in the study was completely 
voluntary and all their information would be de-identified and kept confidential. With the 
participants’ permission, all interviews were audio recorded. The researcher used the interview 
guide to direct the interview and asked follow-up questions based on participants’ responses to 
learn more about their experiences with Fabry disease and to understand their views on newborn 
screening for Fabry disease. Between the first and second parts of the interview, the researcher 
asked the participants to open the educational brochure on newborn screening and the researcher 
went through the brochure with the participants. Recordings of the interviews were transcribed 
verbatim by the same researcher and transcripts were de-identified as they were transcribed. 
3.2.3 Data Analysis 
Transcripts were analyzed via thematic analysis using the steps described by Braun and 
Clarke127. The intent was to generate themes that describe participants’ experiences with Fabry 
disease, their understanding of newborn screening and their attitudes on newborn screening for 
Fabry disease. The researcher coded transcripts in Microsoft Word using the Comments function 
to connect the relevant pieces of transcripts to the corresponding codes and codes and emerging 
themes were tracked in a codebook in Microsoft Excel. Codes were identified and analyzed 
using the inductive approach to analysis, with coding and further analysis being driven by the 
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data and not by a pre-existing question or theoretical scheme127. Themes were identified from the 
codes using the semantic approach, which identifies themes within the surface meaning of the 
data127. Throughout the analytic process, memoing was used to describe the codes and emerging 
themes and to capture ideas about what concepts should be explored in future data analysis. The 
qualitative analysis process was discussed with two researchers who are genetic counselors with 
experience in qualitative analysis and have experience with Fabry disease. The lead researcher 
met regularly to review each coded transcript, memo and the codebook with a genetic counselor 
experienced in qualitative analysis. Any discrepancy between the genetic counselor’s and the 
lead researcher’s perceptions of the codes and themes were resolved until consensus was 
reached. Through this analysis, six themes were identified. 
3.3 RESULTS 
Six participants who have Fabry disease were interviewed for this study. Their ages 
ranged from early 40s to 75 years. Four were female and two were male. Age of diagnosis 
ranged from 7 years to 65 years. Each participant had multiple features of Fabry disease and the 
manner of diagnosis varied among participants. Table 2 describes participants’ Fabry disease 
status.  
Table 2. Demographics of participants 
Participant Age at Outward 
Symptoms 
Age at Diagnosis Diagnosis Gender Disease Status 
P1 None 7 years (“carrier”) 
50 years (affected) 
Family 
history 
Female Renal failure, heart damage, 
cornea verticillata 
P2 Childhood 65 years Family 
history 
Female Acroparasthesias, GI 
symptoms, kidney issues 
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Table 2 Continued 
P3 Teens Early 50s Symptoms Female Fatigue, GI symptoms, 
acroparasthesias, 
hypohydrosis, cornea 
verticillata, cardiomyopathy  
P4 Childhood 49 years Family 
history 
Female Acroparasthesias, heart 
damage 
P5 Childhood 36 years Symptoms Male Hypohidrosis, heat and cold 
intolerance, acroparasthesias, 
kidney failure and kidney 
transplant, heart damage 
P6 None Mid 30s By chance Male Proteinuria 
 
Six themes were identified from the interviews with these participants:  influences of clinical 
spectrum and severity of Fabry disease, support systems, family dynamics, impact of timing of 
diagnosis and treatment availability, knowledge and attitudes towards NBS for Fabry disease, 
and impact of earlier diagnosis. These themes are described below. 
3.3.1 Theme #1:  Influences of clinical spectrum and severity of Fabry disease 
Participants and their families experienced a wide range of clinical symptoms and 
severity of Fabry disease. Their experiences with the disease seemed to influence their lives, 
their understanding of the disease, and the impact of being diagnosed.  
3.3.1.1 Impact of disease features and receiving a diagnosis 
Those who had experienced symptoms since childhood shared how disease features had 
impacted their physical and mental health. For the participants who spent years searching for a 
cause of their health problems, they described their diagnostic odyssey experiences. Participant 5 
said:  
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I’ve seen doctors ever since I was 7 years old for this [pain]. Some said it was like 
childhood pain and some said I’d grow through it.  
 
The features, particularly pain, affected their quality of life, such as the ability to participate in 
school, sports, work, and everyday functioning. They also shared the impact of having 
unexplained symptoms on their mental health. Participant 5 described it as:  
That’s hell when you’ve got a problem and nobody believes you.  
For these individuals, being diagnosed with Fabry disease provided a name for what they were 
experiencing. When asked about the impact of the diagnosis, participant 2 said:  
Just the idea that, I guess I have something to put all of these symptoms that they never 
figured out what was going on. 
 
It also confirmed their feelings that there was something wrong with them. Participant 3 said:  
It puts my mind at ease because I just have always thought that there’s something wrong 
with me, you know like something major, like I had cancer or something weird going on. 
You just get that intuition or something and now I can, now there’s something a name 
there and you can face it and move on.  
 
Participant 3 was the first one diagnosed in her family and after her diagnosis, doctors said her 
mother most likely passed away from Fabry disease. After learning this, participant 3 said:  
My big worry is that my life will end like my mother’s. I don’t want to have that happen. 
That scares me. Because her death was painful, it was just very bad. I mean, so that part 
scares me now that, you know, with that diagnosis. 
 
Other participants and a participant’s child were diagnosed in adulthood prior to 
developing outward symptoms of Fabry disease. The individuals diagnosed after a family 
member’s diagnosis seemed to have a difficult time accepting the diagnosis when they had no 
outward symptoms of the disease, which seemed to make it more challenging to understand the 
need for ERT. Participant 1 said:  
I was like this isn’t true, you know what I mean? Like I don’t have any symptoms. Why 
are you starting me on something that I just don’t have any symptoms for and yeah it 
kind of felt, I don’t know you get kind of paranoid when stuff like that happens. It’s just a 
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sci fi thing and they are trying out a drug on me to see if it’s going to work because it 
does seem super strange. 
 
This participant watched her father pass away from Fabry disease during her childhood and at 
that time she was diagnosed as a “carrier.” When she was diagnosed as affected in her 50s, she 
said:  
When I first found out I was devastated because you know all I imagined was that my 
whole entire life was going to be defined by this disease, how it was going to impact my 
career and my family and everything I just thought, you know, I just imagined the worst.  
 
After she learned more about the disease, participant 1 appeared to eventually accept the 
diagnosis. She described her feelings about knowing the diagnosis due to her family history.  
I feel fortunate that I at least knew what it was because my dad had it. But when I talk to 
these other people, they have no clue and they went to numerous doctors and those 
doctors could not find anything wrong with them.  
 
Participant 6 was diagnosed by chance after a physical examination identified proteinuria.  
I don’t know what most people, how they feel or whatever if they do have Fabry disease. 
Like I said, I felt fine, you know what I mean. I’m probably actually fortunate to have to 
get a DOT [Department of Transportation] physical, you know what I mean, to get to find 
out that I had it for treatment or whatever. 
 
3.3.1.2 Understanding of disease 
Participants’ experiences with the disease seemed to influence some of their 
understandings of Fabry disease. Participant 1 has no outward symptoms.  
I’d say it’s terrible, but you know, these are the things that you can do, you can adjust 
your life and work around these things and be happy […] This to me is something that is 
an inconvenience, but you know, we deal with it.  
 
In contrast, participant 4 has had pain since childhood and in the following, she discusses her 
understanding of Fabry disease.  
They first start having trouble, you know, throughout the body, you know, they always 
cry about their hands and their feet.  
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Other participants seemed to have a broader understanding of the possible spectrum of Fabry 
disease and thought they did not know enough about Fabry disease to identify all of its features. 
For example, participant 3 said:  
You never know if it [symptom] is something that is connected with it [Fabry disease]. 
And you never know what it could be because it could really be something that is 
connected to it.  
 
All participants had some organ damage at the time of diagnosis and they understood the 
seriousness of organ involvement in Fabry disease. However, for some participants, the 
seriousness of organ involvement did not seem to align with their perceptions of their overall 
health when they had no outward symptoms. Participant 1, who has third stage renal failure and 
some heart damage said:  
I go to the gym every day and I teach yoga and you know, I don’t have a single issue […] 
I feel really healthy.  
3.3.2 Theme #2:  Support systems 
The type of emotional and medical support and how much support participants received 
varied among participants. The variability seemed to depend on their families, healthcare 
providers, and support from other sources, like the Fabry community. 
3.3.2.1 Family 
Some participants described how their spouse or other family members were an important 
source of support. Participant 3 said, “My husband was very supportive,” at the time of her 
diagnosis. However, there were varying amounts of support from family members. Some family 
members were dismissive of symptomatic participants prior to diagnosis and remained 
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dismissive or were indifferent to the participant after diagnosis. When asked how the diagnosis 
has impacted his family, participant 5 said: 
I can’t say it really has ‘cause they always wonder ‘what if he weren’t taking the 
medicine.’ My dad’s the kind of guy who believes ‘you don’t even know if you need be 
on that’ you know. I said well I can’t stop it, cause if I stop what if shit shuts down again.  
 
Participants’ family dynamics, support, and attitudes are described further in the “Family 
dynamics” theme section. 
3.3.2.2 Healthcare providers 
Participants described their interactions with a variety of healthcare providers through 
their diagnostic odysseys and after diagnosis. During the diagnostic odyssey, participants shared 
how some doctors did not believe their symptoms, missed symptoms, and made comments 
dismissing their symptoms. Participant 3 said: 
I always had things, little things, going on that, you know, they [doctors] always said oh 
no, you didn’t test positive for this. 
 
Participant 5 saw a specialist for pain and shared the following.  
She gave me issues about the pain meds I was on. And I said I’m constantly in pain every 
day. And I don’t think she totally believed that. And then when they started doing the 
biopsies, she come and apologized for the way she acted. But still don’t take the fact 
away that I had to experience that.  
 
Through their journeys with their symptoms and diagnosis, participants seemed to value 
providers that listened to them, addressed their concerns, explained what was happening, and 
learned about Fabry disease to provide more appropriate care. Participant 4 seemed to appreciate 
the care her geneticist took to provide her with support.  
I used to go that one hospital every 2 weeks [for ERT], but then the taxi driver, the taxi 
company quit taking us down there so it was like 5 months I didn’t have my medicine. So 
then [geneticist] before he left made sure I was getting it in my home, you know. So I get 
it in my home now every other week. 
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Participants seemed to form close relationships with these providers and considered them a part 
of their support system. When talking about the Fabry specialist group, participant 5 said:  
Them people couldn’t be nicer. It’s just something, I consider them family […] they’re 
sweethearts down there. You know, they bring a cake in every time, every birthday. Yeah 
it’s something, really caring people. 
 
Some participants have noticed a lack of knowledge about Fabry disease among their 
primary care providers and some specialists. Participant 3 shared the following.  
My mom, right before she passed away, they got close enough to say it was amyloidosis. 
That was still in the same family, but after I was diagnosed, they said ‘no it wasn’t 
amyloidosis, it had to be Fabry.’ […] They misdiagnosed her. They didn’t test her, you 
know, for that. That isn’t something, cause it’s so rare. 
 
Because of the rarity, some healthcare providers have limited knowledge of Fabry disease and 
this created some challenges for participants. For example, participant 3 also shared: 
I had to find a new doctor. Which was tough, because I had to find one that was willing 
to go through some training and really do some research and find out about my disease.  
 
Participant 2 considered knowledge to be a part of support.  
I just sort of feel left in limbo a little bit […] it comes down to people don’t know enough 
about it. My son just complains that every time he says something to the doctor, they say, 
“oh that doesn’t go with Fabry’s” but when you are reading on Facebook and everyone is 
complaining about the same thing. So you know, that’s part of his problem, also part of 
my problem too. 
 
Some participants have educated their doctors about Fabry disease. Participant 5 said:  
Still people don’t know what Fabry is. I mean I’ve handed out pamphlets to my doctors, 
you know them little booklets. I hand them out to everybody.   
3.3.2.3 Other sources of support 
Most participants sought out other sources of support to supplement what they had from 
their families and healthcare providers. Participant 3 said:  
I have a psychologist that I see. And I was seeing that person at that time [diagnosis], 
which was very helpful. 
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Some participants had attended support groups and meetings for Fabry disease. Participants 
seemed to find varying levels of support from the Fabry community based on where they saw 
themselves on the Fabry spectrum of severity. On one end of the spectrum was participant 1, 
who has had no outward symptoms.  
Sometimes Genzyme will pull people together for little meetings and when I see them 
and I see how debilitated they are, it makes me happy that I actually started [ERT] before 
I had the symptoms. 
 
In the middle of the spectrum was participant 3.  
The support group I have online is wonderful. ‘cause you can just, you can, if you are 
having a bad day, you can just put that out there and people can say well I did this and 
this helped or that helped or have you guys ever had this happen to you, or what is this, I 
don’t understand this. So that kind of stuff really helps.  
 
At the severe end of the spectrum, participant 5 did not seem to find support groups helpful.  
There’s a lot of support groups, but how can I say it? These were guys that worked all 
their life and then developed symptoms later, like somewhere around their retirement or 
in their 30s, in their 40s. see I was messed up from child, I couldn’t go to work and stuff. 
And I had no reason why.  
3.3.3 Theme #3:  Family dynamics 
Family dynamics describe how family members interact with each other and their 
relationships with each other. The family dynamics prior to diagnosis seemed to influence how 
the family reacted to the participant’s diagnosis and how they felt about testing for themselves. 
For participants who had symptoms since childhood, the family dynamics seemed to be shaped 
by how the family dealt with the participant’s unexplained symptoms. These family dynamics 
then appeared to affect how much support the participant had from his/her family. When 
symptoms were present in childhood, several participants described how some family members 
dismissed their symptoms. Participant 3 said:  
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[…] ‘cause my family always told me I was a hypochondriac growing up. 
Similarly, participant 5 shared:  
They [family] kind of blew it off or were like childhood pain or just being lazy, I was 
faking. You know, I was called everything. You know, by my own father. […] cause 
when it was up to my family before I was of age, they you know, my dad would get 
pissed off because I had to go to Pittsburgh to get some kind of test done. So I had to hear 
that all the way down there and the way back.  
 
His symptoms affected his relationship with his siblings.  
Growing up, there was a competition between me and my siblings. But I was always sick 
and I couldn’t cut the grass or do yardwork, so just little things like that. And it really I 
guess irritated them. I’m finding this out now. I didn’t know it then. But I guess it was a 
big problem when I was a child.  
 
The behavior and actions of his family members seemed to isolate the participant within the 
family. When participant 2’s family found out her cousin had Fabry disease, she said:  
The rest of my brothers and sisters told me to get tested because I’d probably be the only 
one that had it. 
 
Participant 2 indicated that her siblings never got tested.   
All participants had told their families about their diagnosis and some shared how they 
educated their family members about Fabry disease. Through these descriptions, it appeared that 
participants wanted to pass on health information pertinent to their family members, explain the 
cause of their symptoms to family members, and get support from their families. The experiences 
participants shared suggested that it took families time to believe the diagnosis or in some cases, 
family members still do not accept it. When participant 3 discussed her diagnosis with her 
siblings, she did not get the reaction she was expecting.  
I really thought I would get a little bit more empathy from like my siblings and things. 
And nothing. It’s like they treat me like nothing is even wrong with me […] I said well 
I’ve been having mini strokes, that’s why I have to have this done or something. And 
none of them had any concern, you know, at all. So that’s been depressing, you know, 
that your family like doesn’t support you. 
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When asked how her siblings initially reacted to the diagnosis, she said:  
Well because they didn’t know anything about it, they just thought it was a bunch of ho 
shmo. And when I said that’s what my mom really had, they didn’t believe it. They said 
no, she had this. And they didn’t believe me. And then when I told them all this 
information about, you know, on the disease and you know, them misdiagnosing her and 
[…] that the chances of me having that were so, I mean first off, it’s a rare disease, but 
it’s even rarer just to have that happen to you. They were like, ok, so then they were 
thinking oh maybe she’s right. But I still have one brother, I have one brother that still 
does not believe that it came from my mom. And that’s, that’s like saying that I’m lying 
that I have this because that’s where it came from. 
 
Participant 3 thought her family would have reacted differently to the diagnosis if she had been 
diagnosed earlier and her mother would have been alive to be tested and diagnosed too. 
They [family] would understand it [disease] better. Especially knowing that my mom had 
it. Because everyone, you know, loved my mom. And my mom is what kept the family 
together. And so, that would have made a huge difference ‘cause they would have really 
learned more about the disease for her. 
 
Participant 5’s family was dismissive of his medical problems before diagnosis and continued 
this behavior after his diagnosis.  
They think that if I would stop taking the medicine, that I would be fine, so. Well they’re 
actually under the theory that when a problem arises, that’s when they’ll take care of it. 
And I keep telling them you need to be on the Fabrazyme to hold all the problems from 
even occurring. And you know, they just don’t listen to me.    
 
Most participants had some family members who did not want to learn about Fabry 
disease and did not want to be tested. There seemed to be a difference between some of their 
families’ attitudes towards testing and the participants’ favorable opinions of NBS for Fabry 
disease. Participant 1 described her attitudes and her family’s attitudes towards testing as the 
following.  
You would be really stupid if you opted out [of NBS for Fabry disease and other later 
onset conditions]. Given the opportunities to make sure that your child is healthy and 
well and having no issues and this is like a little drop of blood out of a heel, I would say 
you would be very very foolish to do that. But then again, I know people, like my own 
family, opted out of a lot of this when they found out I had it. They didn’t want their 
children tested, they didn’t want, all they had to do is produce some blood, but were 
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unwilling to do that. […] They [family] don’t want to know anything about it. And they 
never, like my cousins now all have children who have children and they don’t want to 
know anything about it. Just like their head is in the sand.  
 
Participant 4’s family knew Fabry disease was in the family and she said:  
My brother, he knew he had it and he didn’t want to go get the medicine, you know, he 
didn’t want to worry himself. If he was going to die, he was going to die and it’s what he 
did, he passed on just like my older brother. 
 
Some participants wondered why their family members would not get tested when they had 
children who were at risk. One of participant 3’s brothers has not gotten tested.  
I mean they have a girl, so you would think that they would want to […] if I were the 
mother, I would have gotten the daughter tested. Just to be sure. But I’m not that mother. 
 
A common trend through most of these families seems to be a lack of communication. 
This included not following up with their children who decided not to get tested, families not 
asking how the participant was doing after diagnosis, and the diagnosis not being communicated 
from the family to the participant. Participant 3’s daughter is still deciding about testing.  
I think that after she has kids, that then she would be willing to get tested. That I believe 
she doesn’t want to talk to me about it. So she’s old enough to make that decision for 
herself. 
 
Participant 4 was adopted early in life and had limited contact with her biological family, which 
led to a delay in her diagnosis. After her aunt told her, participant 4 said:  
Why didn’t you let us know when we were younger. Then we could have got it [ERT] 
started or when they first came out with it. But there was never no answer. 
3.3.4 Theme #4:  Impact of timing of diagnosis and treatment availability on attitudes 
towards NBS 
The timing of when participants were diagnosed and the availability of treatments 
specific to Fabry disease seemed to impact their attitudes towards NBS for Fabry disease. All 
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participants were diagnosed with Fabry disease as adults, after ERT and oral chaperone therapy 
became available, and all had some organ damage at the time of diagnosis. Receiving a diagnosis 
led to all participants getting treatment specifically for Fabry disease. Participant 4 said:  
I think the medicine is really great. I really do. For people that have the Fabry disease, I 
think it’s really good, ‘cause it keeps me going, you know. I mean I got to have it the rest 
of my life, but if it keeps me going and keeps me kicking it’s good.  
 
Multiple participants shared their understanding that ERT maintains their organ status, but 
cannot reverse organ damage. Participant 3 said:  
The sooner you get started, the better off you are because then it can help prevent stuff 
going on before it happens. Don’t wait until the symptoms start because then you’ve 
already had some damage to your body. 
 
The availability of ERT seemed to have an impact on participants’ answers about NBS for Fabry 
disease. Based on their experiences, all participants were in favor of NBS for Fabry disease 
because an earlier diagnosis would mean earlier ERT. Participant 5 said:  
By the time I got on it [ERT], the FDA had just approved it. So I kind of got on it right 
when they came out with it anyhow. 
 
Some mentioned how they would want parents deciding about NBS to know that there is a 
treatment to prevent disease features. Participants had varying reactions to when ERT would 
begin in an asymptomatic child. Some wondered when ERT would begin if a child had no 
symptoms. Participant 1 said:  
I kind of want to know how long, how soon before the child would need to start 
replacement therapy. Like, you know, for me it obviously took 50 years for things to 
start. So, what’s the timeline, I guess is what I’m looking for.  
 
Other participants wanted treatment to begin right away. Participant 5 said:  
I think that would piss me off a little bit…if the doctors knew I had it and they wanted to 
wait until symptoms, I think that would upset me a bit. Because the treatment can hold 
off problems. 
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3.3.5 Theme #5:  Knowledge and attitudes towards NBS for Fabry disease 
Participants were asked what they knew about NBS before participating in this study and 
their opinions on NBS for Fabry disease and other late-onset conditions. Their responses to these 
questions and their experiences with Fabry disease provided insights into their reasons behind 
their opinions on NBS for Fabry disease. 
3.3.5.1 Knowledge of NBS 
Two participants had heard Fabry disease was being added to NBS and seemed to have a 
good understanding of the general purpose of NBS. They thought the purpose of NBS was for 
awareness and to be able to start treatment before the condition affects cognitive and physical 
development. Four of the participants had not heard of NBS before participating in this study. A 
number of the participants were not sure what conditions NBS looks for, but some guessed that it 
looked for genetic conditions. A couple participants thought it looked for either organ damage or 
malfunctions in the body and that a diagnosis via NBS would mean ERT could be started earlier.  
3.3.5.2 Opinions on NBS for Fabry disease 
All participants were in favor of NBS for Fabry disease before and after going over the 
educational brochure. Most mentioned earlier treatment and awareness of symptoms as reasons 
for NBS. Participant 2 described it as:  
I think it’s a good idea because then you’re aware and when the symptoms do appear, 
then you can start treatment before something happens that cannot be fixed I guess is the 
easiest way to say it.  
 
Some said they would rather have an answer about whether their child has Fabry disease at birth 
and participant 5 said:  
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I don’t see why it’s such a big deal, you know, why don’t they just do it [NBS for Fabry 
disease]. 
 
Five participants thought Fabry disease met the NBS definition of urgency because of the 
seriousness of organ involvement. Participant 1 thought Fabry disease did not meet the NBS 
definition of urgency and said:  
I don’t think it’s urgent that the baby, like a newborn, has the procedures in infancy. But I 
think early. 
 
About half said NBS for later-onset conditions “should be mandatory” and the other half said 
parents should think carefully about the consequences of not testing if their child has a condition. 
3.3.5.3 Reasons in favor of NBS for Fabry disease 
Participants described several reasons for being in favor of NBS for Fabry disease and a 
diagnosis at birth:  awareness, improved physical functioning, psychological impact, and more 
family support. A number of participants said they would have been more aware of their 
symptoms or their child’s symptoms, with a diagnosis at birth. Participant 2 said:  
I think I would have been a little bit more aware of what is going on and noted if there 
were any symptoms along the way. 
 
Participant 3 said:  
[with a diagnosis via NBS] you are more aware of the body and what are symptoms of 
the disease. Because I had little symptoms too. I mean even when I was younger … And 
if I’d been diagnosed as a baby, that’s possible that those are things that could have been 
detected a lot sooner.  
 
Some participants shared how a diagnosis at birth would have impacted their physical 
functioning. Participant 4 said:  
I would have been working for longer than I was and I wouldn’t have as much problems 
and those surgeries like I had.  
 
Participant 5 said:  
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I think if I was tested sooner, or I mean if I could have been tested as an infant, none of 
this damage might have occurred. I truly believe that. 
 
Some participants also shared how a diagnosis at birth would have had a psychological impact. 
Participant 5 said:  
My kidneys might not have shut down, my heart would not be bad, I don’t think any of 
that would have happened. And the psychological with that. Yeah I had to deal with that 
and I had doctors, parents and everybody tell me that there’s nothing wrong. I knew in 
my heart that there was something wrong. I mean I could tell you stories you would not 
believe. Yeah, it’s just, it’s hell. […] The screen would take care of that [people believing 
you].  
 
Some believed their families would have reacted differently to Fabry disease and their symptoms 
and the family would have been more supportive. Participant 3 thought Fabry disease’s non-
specific symptoms were a reason to be in favor of NBS for Fabry disease.  
They’re [symptoms] hard to tell what they are. So you really need that test, ‘cause there’s 
so many little things going on with me that I, you couldn’t tell that there were. And if it 
hadn’t been for my eye pattern [identified by an ophthalmologist], I still wouldn’t know 
what’s wrong with me. 
3.3.5.4 Attitudes towards NBS results 
Participants’ attitudes to different NBS results seemed to vary by experiences with Fabry 
disease, personality, and previous understanding of NBS. The two participants who had heard of 
NBS before this study had slightly different reactions to NBS results. Participant 2 said:  
I would rather have a negative result than any of the others. It’s just like the other 
newborn tests that they give, you know, and once you’ve had that result then you don’t 
have to worry about that anymore.  
 
About a false positive newborn screen, participant 3 said:  
I’d be relieved. And I know that sometimes things like that happen. 
The other four participants did not seem to completely trust NBS results. Their responses to NBS 
results varied:  some wanted to have more testing in the future while others would be anxious 
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until more testing was done to confirm the results. About a negative newborn screen, participant 
1 said:  
I would check up on that on a regular basis ‘til I was absolutely positively sure. 
Participant 6’s response to all types of newborn screen results was:  
I wouldn’t mind getting it checked out down the road just to make sure, you know, that 
maybe it doesn’t show up real early in life and that kind of thing. 
3.3.5.5 Information at the time of diagnosis or positive newborn screen 
Based on their experiences, participants would recommend families talk to a specialist 
and genetic counselor initially to learn more about Fabry disease. Participant 6 said:  
Probably a specialist [after diagnosis through NBS], I would think you know, they know 
what exactly is going on. They [parents] would get more out of that I think. 
 
Some also recommended connecting families to support groups or others with Fabry disease for 
the family to have another source for information. Participant 1 said:  
For young parents for when their child is diagnosed, there needs to be somebody there 
who has Fabrys to talk to them. So that they can say like “look I’m 60, I’m 70, I’m 50 or 
whatever and I’m still doing just fine” or even some of the young children I have met, 
they need to be there to talk to these parents and say “everything is going to be good, you 
just need to do these certain kinds of things” […] there needs to be somebody there who 
has the disease, who has gone through everything, who can help talk to them. 
 
In contrast, participant 5 discussed the need to educate parents about the serious manifestations 
of Fabry disease.  
I think they [parents deciding about NBS] should actually meet somebody with Fabry 
that’s had the transplant, or you know, with the heart or the kidneys or whatever.  
3.3.6 Theme #6:  Impact of earlier diagnosis 
Participants described how they would raise a child diagnosed with Fabry disease. Many 
said the diagnosis would not affect the way they raised their child, but then described actions that 
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could be considered more vigilant than usual and they discussed how they would advocate for 
their child. 
3.3.6.1 Vigilance 
Many participants discussed actions that could be described as being more vigilant if 
their newborn child were diagnosed:  closely monitor the child for any signs of Fabry disease, 
take the child to the doctor more often, wonder if any cough or sickness was something serious 
connected with Fabry disease, and re-check test results. When asked how a diagnosis before the 
appearance of symptoms would affect how she raised a child, participant 2 said:  
I think that she [mother] would be a little hypervigilant and looking for symptoms that 
might not have even occurred. 
 
Participant 1 said:  
You’re looking at a newborn and like I thought for sure I was going to kill my kid before 
she reached 4, you know every time she had a cough or sniffles. I thought ‘oh my god, 
I’m going to kill her, she’s going to die, I don’t know what I’m doing’ and then that 
becomes even larger when you know your child has a disease. Every cough, every sniffle, 
every temperature, you know, oh my god is this related to [Fabry disease]. 
 
Their descriptions of what they would do in a hypothetical situation resembled what they had 
experienced in real life. Participants with younger family members who had not been tested 
described being hypervigilant with these family members for signs of Fabry disease. One 
participant who was initially diagnosed as a “carrier” pursued invasive prenatal testing at a time 
when it was still a new procedure and had her daughter re-checked later in life to confirm the test 
results.  
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3.3.6.2 Advocate for child 
Participants said they would advocate for their child by watching for symptoms, listening 
to their child’s concerns, moving closer to a medical center, talking to doctors, and asking 
doctors for ERT to prevent manifestations of Fabry disease. Participants’ descriptions of what 
they would do in a hypothetical situation seemed to represent how they would want their child’s 
experiences with Fabry disease to be different than their experiences. Participant 1 said:  
If I lived out in the middle of nowhere/no mans land, I couldn’t get any help, I would 
move to a center where within miles I’d be able to, yeah I’d move. You know those are 
options that are important to me. They’ve made my life easier and those are some 
recommendations I’d make to people. 
 
Participant 4, who experienced a delay in receiving a diagnosis because her family did not tell 
her about the presence of Fabry disease in the family, said:  
I would take the baby when it goes to the doctor’s for the first time and explain it to the 
baby doctor saying, you know, same way I have it, could you please check my daughter 
or him that if he has it so they could get started right away [on ERT]. 
 
Participant 5, whose family did not believe his symptoms in childhood, said:  
Well if I had a child and he had Fabry and was saying what I was saying, I think I would 
have took better care of him, you know. And I didn’t have that. I was always pushed 
away. 
3.3.6.3 Life decisions 
Some participants mentioned how the diagnosis would have impacted their decisions on 
having children. Participant 1, who was initially diagnosed as a “carrier”, said she would want to 
talk to a genetic counselor.  
I’d want to know more about, like I stopped, I was already 31 when I had [participant 1’s 
daughter] so I was content…I didn’t know anything, so I just stopped at one. If I had 
more information and more people who could have talked to me about my life, I might 
have had more children. 
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Participant 3 said if she had been diagnosed at birth via NBS:  
I would have definitely made my decision on having children probably.  
3.4 DISCUSSION 
Participants in this study were asked about their experiences with Fabry disease, their 
knowledge of NBS, and their opinions on NBS for Fabry disease. Their responses regarding 
these topics provided insights into their reasoning behind their opinions about NBS for Fabry 
disease. 
3.4.1 Theme #1:  Influences of clinical spectrum and severity of Fabry disease 
This study’s participants seemed to have similar experiences with Fabry disease as 
participants in other studies on Fabry disease. Participants who had outward symptoms described 
how these symptoms interfered with their participation in sports and holding down jobs and this 
is consistent with results from other studies on quality of life and Fabry disease49,71,73,74. 
Participants in this study and other studies had varying reactions to the diagnosis based on the 
symptoms they had prior to diagnosis25,26,75. Those who had noticeable symptoms prior to 
diagnosis seemed relieved with the diagnosis because it provided a name and reason for what 
they were experiencing25,26,75. The participants who had no noticeable symptoms before 
diagnosis seemed to have a more difficult time accepting the diagnosis25,26,75. Participants in this 
study had some cryptic organ damage at diagnosis, which may explain why they came to accept 
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the diagnosis and need for ERT, whereas asymptomatic participants in other studies felt the 
diagnosis led to labeling and medicalization25. 
3.4.2 Theme #2:  Support systems 
Participants in this study shared their perceptions of the support they receive from their 
family members and from their healthcare providers. Research on motivations behind disclosing 
genetic test results to family members has found the main motivations include familial obligation 
to share health information and seeking social support128,129. Some participants’ responses 
suggested these were their motivations for sharing the diagnosis with family. Multiple 
participants shared their frustration and sadness that some or all family members did not offer 
support after the participant’s diagnosis; this seemed to affect the emotional and psychological 
health of participants’ experiences with Fabry disease. These experiences are consistent with 
research on family support and chronic illness that have found that there are better outcomes 
when there is more family support130,131. 
Participants in this study seemed to define knowledge of Fabry disease among their 
healthcare providers as a form of support. Some participants in this study and other studies 
noticed a lack of knowledge about Fabry disease among their healthcare providers75,76. Before 
they were diagnosed, participants shared how doctors missed their symptoms or seemed 
dismissive of their symptoms75,76. After being diagnosed, participants in this study and other 
studies noticed their healthcare providers lacked knowledge about Fabry disease and some were 
frustrated by this lack of knowledge75,76.  
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3.4.3 Theme #3:  Family dynamics 
This study provided new insights into the dynamics in families affected by Fabry disease. 
A family’s beliefs about illness range from viewing illness as a part of life to deal with to 
viewing illness as a threat to be avoided132. From participants’ descriptions, some families 
seemed to accept the diagnosis as something to deal with, while other families seemed to avoid 
the illness and its consequences. Avoiding the diagnosis may have also been a coping 
mechanism. Participants’ families seemed to use disbelief, deferral, and dismissal as coping 
mechanisms after they learned of the diagnosis133. Disbelief is used as a coping mechanism when 
symptoms or signs of the disease are absent and a lack of signs makes it difficult to accept the 
information133. When disbelief is used as a coping mechanism, acceptance of the information 
usually comes with more time and information. Participant 3’s siblings seemed to use disbelief 
as a coping mechanism after they learned about her diagnosis. Participant 3 had symptoms since 
childhood and she was the first person diagnosed with Fabry disease in her family. After her 
diagnosis, participant 3 explained to her siblings that her symptoms and their mother’s death 
were caused by Fabry disease. It seemed like her siblings did not initially believe participant 3 
about Fabry disease because participant 3 and her mother had different symptoms. Most of her 
siblings came to accept the diagnosis as they learned more about it. When deferral is used as a 
coping mechanism, individuals put off accepting the diagnosis and making decisions about it 
because the implications of the diagnosis are difficult to handle133. Participant 3’s daughter may 
be using deferral as a coping because she has not gotten tested and participant 3 speculated her 
daughter is waiting to get tested until she has children. Individuals who use dismissal as a coping 
mechanism disregard recommendations and do not value the information provided by healthcare 
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providers133. Participant 5’s family may be using dismissal as a coping mechanism since they 
thought ERT was not needed to treat or prevent symptoms.  
Families’ views of Fabry disease may be shaped by their family histories when they have 
seen multiple generations affected with the disease. These families have experienced loss and 
grief over multiple generations and they may not have connected these medical problems to a 
genetic cause129,134. The first person who gets genetic testing connects a genetic etiology to the 
family’s medical problems and the family has an emotional transition as it processes this 
information and changes how the family views the medical problem134. As the first person 
diagnosed in her family, participant 3 linked the family’s various medical problems to Fabry 
disease and it took time for her siblings to accept the diagnosis. Some families in this study were 
diagnosed in the transition from no treatment for Fabry disease to ERT becoming available. 
Participants described the painful deaths older family members had before ERT was available 
and without knowing more about advances in treatment, these experiences may influence how 
untested family members view Fabry disease134.  
Research on family communication and genetic conditions has found that relationships 
and tensions that existed before diagnosis affect communication about the genetic 
condition129,130,135,136. Conflicts that existed prior to diagnosis or a family member’s death related 
to the diagnosis affected family communication about the genetic condition135. The results from 
this study are consistent with this research. In this study, families that dismissed participants’ 
symptoms before diagnosis continued to be dismissive or in some cases, indifferent. 
Participants were not explicitly asked in this study why their family members had or had 
not decided to get tested, but previous research on familial attitudes towards genetic testing 
provides relevant information. A study on siblings’ perceptions of risk for hereditary 
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hemochromatosis (HH), a genetic condition that leads to excess iron storage and has non-specific 
symptoms like Fabry disease, found that siblings had low perceived susceptibility to HH because 
of denial, their doctor did not think they had it, lack of knowledge, or not experiencing the same 
health problems as the diagnosed sibling137. The emotional aspects of the disease, disease 
severity, and age of onset also influence testing decisions134. Relationships change based on who 
in the family gets tested, their results, and who does not get tested134. Participants in this study 
seemed to feel isolated in their families when family members did not get tested or if family 
members tested negative. A study on family communication and genetic conditions and this 
study noticed increased tension when participants thought family members (i.e. siblings) should 
get tested to provide information for younger family members (i.e. participants’ nieces and 
nephews)135.  
There were noticeable differences in participants’ views on NBS for Fabry disease and 
some of their family members’ views on testing for Fabry disease. On one hand, participants 
thought NBS for Fabry disease should be mandatory or would strongly suggest to parents not to 
opt out of NBS for Fabry disease. On the other hand, some of their family members seemed to be 
against testing for themselves and for their children after learning Fabry disease is in the family. 
Some participants noticed the discrepancies between their views on NBS for Fabry disease and 
their family members’ attitudes towards testing. These participants seemed perplexed by family 
members’ decision to not get tested, particularly when, in their view, testing to only involves a 
blood sample. 
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3.4.4 Themes #4 and #5:  Impact of timing of diagnosis and treatment availability on 
attitudes towards NBS & Knowledge and attitudes towards NBS for Fabry disease 
Multiple studies have asked individuals their opinions on NBS in general and for specific 
conditions, but these studies did not assess participants’ understandings of NBS22–24,26,122. In this 
study, participants were asked what they knew about NBS before going through the educational 
brochure and after the educational brochure were assessed for increases in their understanding of 
NBS. Most participants seemed to understand the general process after the educational brochure, 
but one participant still thought NBS checks a newborn’s genes and organs. All participants 
seemed to understand that a diagnosis via NBS would lead to earlier treatment. Most participants 
did not seem to understand the NBS definition of need for urgent intervention to prevent 
complications, which was defined for them as “infants at immediate risk of developing life-
threatening symptoms associated with a serious condition.” Five participants said Fabry disease 
met the definition of urgency because of heart and kidney damage, even though these 
participants did not have heart or kidney damage until adulthood.  
All participants in this study were in favor of NBS for Fabry disease before and after the 
educational brochure. Participants seemed to have similar reasons for being in favor of NBS for 
Fabry disease as other studies that investigated opinions towards NBS. The clinical benefit of an 
early diagnosis leading to earlier initiation of ERT was mentioned by participants in this study 
and studies on NBS in the general population and NBS for MPS disorders22,23,121. Participants in 
this study and other studies on MPS and Fabry disease mentioned the psychological benefits of 
earlier diagnosis and avoiding the diagnostic odyssey as reasons for being in favor of NBS23,25. 
Despite some participants’ lack of trust in NBS results, indicated by their desire to have their 
child tested later in life, all participants in this study support NBS for Fabry disease. 
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Despite attempts by the interviewer to elicit comments on the potential harms of an early 
diagnosis well before treatment would start, participants did not comment on the potential harms 
that were presented in other studies22,23,25. Participants in other studies mentioned how an earlier 
diagnosis would change how the child is viewed and could lead to the child being labeled22,23,25.   
3.4.5 Theme #6:  Impact of earlier diagnosis 
Participants in this study were asked how a diagnosis at birth would affect how they 
raised their child given the concerns raised by other studies19,21–23,25,118. They said the diagnosis 
would not change how they raised their child, but their descriptions of possible actions they 
would engage in could be characterized as being hypervigilant. For example, taking any cough or 
sniffle as a possible symptom, moving to be closer to a medical center, and taking the child to the 
doctor more frequently. Participants in this study did not mention how these actions would 
impact the child and family. These responses are in contrast to the experiences of families with a 
child diagnosed with a genetic condition at birth or soon after126,138–140. Studies in this population 
found that it took parents time to mourn the loss of a healthy child and build a parent-child 
relationship138,139. Instead of the child being the focus in the child’s early years, the disease and 
healthcare providers became the focus138,140. With a late-onset, variable condition like Fabry 
disease, there is more uncertainty that may make parents either hypervigilant or skeptical of the 
need for evaluations and follow-up126. 
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3.4.6 Limitations 
One limitation of this study is the size of the sample and participant demographics. All 
participants were older, ranging from 40s to 70s, had Fabry disease, and had some heart and/or 
renal damage at the time of diagnosis. These factors may have influenced their opinions on NBS 
for Fabry disease. There also may have been selection bias because the participants who 
volunteered to participate in the study were willing to speak about their experiences with Fabry 
disease during an hour-long interview. Within the interviews, participants were asked many 
questions about their experiences, knowledge of NBS, and opinions on NBS for Fabry disease. 
However, due to participants sharing more than anticipated about their families’ experiences 
with Fabry disease and having one hour for each interview, there were limitations on the depth 
and quantity of the questions that could be asked, as well as limited time to re-contact 
participants following preliminary data analysis. 
3.4.7 Future directions 
The results of this qualitative exploratory study can inform future studies on Fabry 
disease and NBS. Future studies can continue to gain an understanding of the opinions on NBS 
for Fabry disease and family dynamics from younger adults with Fabry disease and unaffected 
parents of a child who has Fabry disease. Participants in this study alluded to their siblings’ 
views on Fabry disease; future studies could ask siblings of individuals with Fabry disease about 
their opinions. Since some states have begun NBS for Fabry disease, future studies could focus 
on parents of a child diagnosed with Fabry disease via NBS to learn their opinions on NBS for 
Fabry disease and how the diagnosis impacts the child and the family, particularly related to 
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evolving family dynamics in the face of early identification of asymptomatic individuals not yet 
eligible for ERT. Participants’ responses in this study revealed some gaps in their understanding 
of NBS and the current status of knowledge and guidelines for Fabry disease. Moving forward, 
parent advocates could be educated about these topics and why genetics healthcare providers, 
bioethicists and NBS researchers have concerns about NBS for Fabry disease. 
3.5 CONCLUSIONS 
As conditions are added to NBS panels, it is important to understand the opinions of 
different stakeholders, including people who have been affected by the condition. This study is 
the first qualitative study to explore knowledge and attitudes towards NBS for Fabry disease. 
Participants’ responses and experiences provided insights into how their family dynamics have 
been influenced by Fabry disease, their knowledge of NBS, and their reasons for wanting NBS 
for Fabry disease. The results of this qualitative study can inform future studies on this topic and 
aid state NBS programs and genetics healthcare providers as they consider and prepare for NBS 
for Fabry disease.   
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4.0  RESEARCH SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH 
The goal of this qualitative study was to gain a more complete understanding of the 
reasoning of adults with Fabry disease regarding the appropriateness of newborn screening 
(NBS) for Fabry disease and to assess their knowledge of NBS. In the process, more was learned 
about participants’ and their families’ psychosocial concerns related to Fabry disease. The results 
of this study can provide guidance to public health decision-makers regarding NBS for Fabry 
disease and future genetic counseling research and practice for Fabry disease. 
4.1 RESEARCH SIGNIFICANCE TO GENETIC COUNSELING 
During their interviews, participants were asked about their experiences with Fabry 
disease and the types of counseling and support they would want if their child was diagnosed 
with Fabry disease through NBS. Participants’ descriptions of their experiences with Fabry 
disease revealed psychosocial concerns related to their families’ dynamics and their families’ 
attitudes towards clarification of their own disease status through cascade testing. These 
psychosocial concerns and responses about information desired at the time of a NBS diagnosis 
can help inform future studies on Fabry disease and guide genetic counseling for families with 
Fabry disease. 
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The information and type of support participants would want after a positive newborn 
screen or diagnosis were congruent with current genetic counseling practices for NBS. 
Participants said they would want to talk to a specialist and genetic counselor to learn more about 
the disease and next steps for treatment and management. Many participants said they would 
want to be connected to support groups to learn more about the disease. Participants’ responses 
about support groups provided insights into what types of support groups to suggest to families 
of a newborn diagnosed with Fabry disease. Given the clinical spectrum of Fabry disease, some 
participants indicated it would be helpful to meet people with Fabry disease who are affected 
differently by the disease. However the participant at the severe end of the spectrum did not 
seem to find it helpful to meet people from the milder end of the spectrum. NBS for Fabry 
disease will identify families from across the clinical spectrum of Fabry disease, such as families 
with late-onset variants and those who may have experienced many of the disease’s non-specific 
symptoms. Participants also expressed different preferences for support group meeting formats, 
in person versus online. The results of this study suggest that it is important to consider what 
type of support the family desires and what experiences they have had with Fabry disease before 
NBS. 
While a few studies have researched quality of life and psychosocial concerns in 
individuals with Fabry disease, not many have explored families’ experiences with Fabry 
disease14,49,71,73–76. The results of this qualitative study provided insights into the experiences and 
psychosocial concerns of families diagnosed with Fabry disease through multiple transitions:  
from no treatment to ERT becoming available, from heterozygous females being referred to as 
“carriers” to affected, and from no known cause for symptoms to the diagnosis explaining 
symptoms. These transitions affected how the participants and their families viewed Fabry 
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disease. Research on transitions and genetic conditions has found that individuals can feel 
isolated after a diagnosis, the amount of support from family and peers made a difference, and 
adjustment to the diagnosis occurs in stages141,142. Future studies on Fabry disease and genetic 
counseling can continue to explore these psychosocial concerns and family dynamics, 
particularly at times of transitions.  
4.2 RESEARCH SIGNIFICANCE TO PUBLIC HEALTH 
The addition of Fabry disease to some states’ NBS panels has broadened the perspective 
of Fabry disease from a rare genetic condition to a more general public health concern. The goals 
of this study included gaining an understanding of the views of one stakeholder group about 
NBS for Fabry disease, adults who have Fabry disease, and assessing their knowledge of NBS. 
As states and their NBS programs contemplate adding Fabry disease to their state’s NBS panel, 
the results of this study can inform three of the ten essential public health services:  inform, 
educate, and empower people about health issues; mobilize community partnerships and action 
to identify and solve health problems; and develop policies and plans that support individual and 
community health efforts.   
Related to the first essential public health service, “inform, educate, and empower people 
about health issues,” the results of this study identified two stakeholder groups that can be 
educated about NBS and Fabry disease. This study elicited participants’ understanding and 
knowledge of NBS for Fabry disease. Their responses revealed gaps in their knowledge and 
understanding of the purpose of NBS. Most participants thought Fabry disease met the NBS 
definition of urgency because of organ involvement in Fabry disease, even though NBS urgency 
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refers to serious medical concerns in the first few days to weeks of life and the participants in 
this study were not affected by organ involvement until adulthood. Participants also did not seem 
to understand how Fabry disease differed from other conditions screened for by NBS. They also 
did not seem to understand the concerns other stakeholders, like genetics healthcare providers 
and bioethicists, have about NBS for Fabry disease. The concerns of these stakeholders include 
the emotional distress following a newborn’s diagnosis, the psychological harms of diagnosing a 
child with a late-onset condition, and over-medicalization of the diagnosed child19–21,118. Moving 
forward, adults with Fabry disease and parents with a child who has Fabry disease can be 
educated about the purpose of NBS and the concerns other stakeholders have about adding Fabry 
disease to NBS. 
While sharing their experiences with Fabry disease and their opinions on NBS for Fabry 
disease, participants noticed a lack of knowledge about Fabry disease among some of their 
healthcare providers. Some of the participants were in favor of NBS for Fabry disease because 
healthcare providers may not otherwise recognize and diagnose someone with Fabry disease. 
After they were diagnosed, some participants mentioned their healthcare providers, both PCPs 
and specialists, lacked knowledge of Fabry disease. As Fabry disease is added to NBS panels, 
healthcare providers can be educated about Fabry disease and provided with up-to-date 
resources. This is detailed further in the public health essay in the next chapter. 
For the second essential public health service, “mobilize community partnerships and 
action to identify and solve health problems,” partnerships can be formed with healthcare 
providers in states considering NBS for Fabry disease to identify the education and support 
healthcare providers would want through the process of implementing NBS for Fabry disease. 
Stakeholder groups for NBS for Fabry disease, like adults with Fabry disease, parents with a 
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child who has Fabry disease, genetics healthcare providers, and NBS programs, can form 
partnerships to educate each other and identify ways to work collaboratively to solve problems 
related to Fabry disease and public health. As these stakeholders work together, the third 
essential public health service, “develop policies and plans that support individual and 
community health efforts,” can be worked on to develop policies and plans for NBS for Fabry 
disease that are agreeable with these various stakeholder groups.     
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5.0  PUBLIC HEALTH ESSAY:  FACTORS TO CONSIDER AS PENNSYLVANIA 
AND OTHER STATES CONTEMPLATE NEWBORN SCREENING FOR FABRY 
DISEASE 
Pennsylvania amended the Newborn Child Testing Act in 2014 to include six lysosomal 
storage disorders (LSDs): Fabry disease, Pompe disease, Krabbe disease, Gaucher disease, 
mucopolysaccharidosis type I (MPS I), and Niemann-Pick disease types A and B, to the newborn 
screening (NBS) panel110. The state began screening for Pompe disease in February of 2016 and 
the other LSDs will be added to the NBS panel as Pennsylvania’s Newborn Screening and 
Follow-up Technical Advisory Board (NBSTAB) confirms that appropriate screening tests and 
follow-up protocols are in place110. As Pennsylvania and other states consider if and when to 
begin NBS for Fabry disease, they can assess the experiences and challenges of states and 
countries that have initiated screening for LSDs. These experiences reveal the infrastructure and 
resource needs and stakeholders at each step of the newborn screening process for Fabry disease. 
The steps include the laboratory screening process including short-term follow-up of positive 
screens including confirmation of diagnosis, education of healthcare providers about NBS for 
Fabry disease, screening of at-risk family members after a newborn is diagnosed, and long-term 
follow-up for newborns and family members diagnosed with Fabry disease after NBS.  
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5.1 SHORT-TERM FOLLOW-UP ON POSITIVE SCREENS 
NBS staff, and healthcare providers are involved in the short-term follow-up of newborns 
with abnormal NBS results143. Data from pilot studies and NBS programs for Fabry disease have 
found that current technologies and methods have a similar ratio of true positives to false 
positives as compared to other newborn screened conditions29,99,102,104. Although NBS yields a 
similar true positives to false positives ratio, these NBS programs and pilot studies did not 
anticipate the higher number of positive screens for Fabry disease that corresponds with an 
incidence of 1 in 3000 people versus the previous estimated incidence of Fabry disease of 1 in 
40,000 males28,30,99. 
For each positive newborn screen, short-term follow-up involves multiple stakeholders, 
their time, and resources: NBS program staff, the newborn’s PCP, a specialist for that condition, 
genetic counselors, pediatric nurses, dietitians in some cases, resources and personnel for 
confirmatory testing, and the newborn’s family. As Pennsylvania and other states consider 
implementing NBS for Fabry disease, they will need to evaluate the capacity of the LSD 
specialty clinics in the state to provide short-term and long-term follow-up for the number of 
positively screened patients for Fabry disease. States may also determine what steps the state and 
LSD specialty clinics need to take to prepare as NBS for Fabry disease is implemented. 
Various methods have been proposed and used to reduce the number of false positive 
screens for Fabry disease. One method utilizes the Region 4 Stork Collaborative Project (R4S). 
R4S was developed as a system to interpret analyte ratios to improve the screening predictability 
for metabolic disorders involving amino acids and acylcarnitines, primarily to reduce false 
positive screens16. This project has recently expanded to include LSDs and some of the pilot 
studies on NBS for LSDs are sharing their data with R4S16,95. R4S could be integrated into the 
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workflow of state NBS programs to interpret abnormal Fabry disease screens and reduce the 
number of false positives that are called out. Alternatively, Missouri’s NBS program created an 
algorithm to reduce their number of false positives for Fabry disease and other LSDs99. As part 
of this algorithm, a newborn’s dried bloodspot is re-tested after a positive screen and the average 
enzyme level from the two tests is assessed and compared to enzyme levels for other LSDs on 
NBS run on the same assay99. Newborns who are considered high-risk after this assessment are 
referred to one of the state’s genetic referral centers99. 
Pennsylvania’s Newborn Screening and Follow-Up Technical Advisory Board 
(NBSTAB) LSD Screening Workgroup has estimated the number of positive screens for LSDs 
each LSD referral center will see, possible methods to reduce false positives and turnaround time 
for confirmatory testing, and short-term and long-term follow-up procedures for newborns with 
Fabry disease (G. Vockley, personal communication, April 2017). Pennsylvania’s plan to reduce 
false positives will utilize R4S and adding second-tier testing for LSDs on the NBS panel (G. 
Vockley, personal communication, April 2017). In second-tier testing, positive screens reflex to 
a more specific test, such as measuring more analytes or DNA sequencing to check for common 
pathogenic variants1.  
5.2 FAMILY SCREENING 
The newborn’s diagnosis following NBS will lead to cascade screening for Fabry disease 
in the family. Because the newborn may be the first person to be diagnosed with Fabry disease in 
the family, the subsequent screening of at-risk family members will increase demands on the 
state’s genetics referral centers’ resources and infrastructure. The newborn may be the first 
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person to be diagnosed with Fabry disease in the family. Data from NBS programs and research 
studies indicate that Fabry disease is underdiagnosed and has a higher incidence of late-onset 
variants than previously recognized13,27,30,99,102. In the Italian NBS pilot study, researchers 
conducted family studies on all 12 diagnosed newborns and reported that all 12 mothers were 
heterozygotes and that multiple families had histories of cardiac or renal disease that are now 
attributed to Fabry disease102. On average, five family members are expected to be diagnosed 
after the index case, the newborn, is diagnosed in the family125.     
Cascade screening in the family would begin with the newborn’s parents. Given Fabry 
disease’s X-linked inheritance pattern, Missouri’s NBS follow-up procedures first screen the 
diagnosed newborn’s mother with a clinical evaluation and molecular testing47,113. These follow-
up procedures, however, did not specify what happens when a newborn female is diagnosed with 
Fabry disease, in which case either the newborn’s mother or father may be affected. From the 
mother’s test results, other at-risk family members can be tested. Any older siblings of the 
diagnosed newborn who were not screened at birth would also be tested. For each family 
member, there is bloodwork and results disclosure. Male relatives can be screened and diagnosed 
from testing -Gal A levels in the blood, but female relatives must undergo molecular testing 
because 1/3 of heterozygous females may not have low blood -Gal A levels10,60,61.   
As Pennsylvania and other states contemplate NBS for Fabry disease, the state’s NBS 
program and medical genetics clinics will need to consider how to handle the number of family 
referrals that will come in following a newborn’s diagnosis. Prior to NBS for Fabry disease, at-
risk family members of a diagnosed individual would undergo a full clinical evaluation with a 
genetic counselor and a geneticist during their screening appointment. With the higher than 
expected number of newborns diagnosed in Missouri, the state’s genetics referral centers are 
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considering how to re-work the current workflow to test the newborns’ at-risk family 
members113. For example, they have considered ordering testing for at-risk family members 
without a genetics clinic visit or having only the genetic counselor see these family members113. 
At-risk family members diagnosed with Fabry disease will have evaluations with the genetics 
clinic and other specialties that deal with the organ systems affected in Fabry disease, like 
cardiology and nephrology. Similar to the genetics clinics, these specialists will also be impacted 
by the number of family members diagnosed after the newborn, particularly in rural areas where 
there may be limited access to specialists. 
5.3 LONG-TERM FOLLOW-UP FOR INDIVIDUALS WITH CONFIRMED 
DIAGNOSIS 
From a public health perspective, there are multiple concerns with the long-term follow-
up and management of individuals diagnosed with Fabry disease through NBS. Most conditions 
on NBS diagnose the newborn with a condition and identify one or both parents as carriers. In 
these cases, long-term follow-up after NBS only involves follow-up management for the 
diagnosed newborn. Unlike those conditions, Fabry disease is an X-linked condition that affects 
hemizygous males and heterozygous females, which means a parent and other relatives will 
likely be diagnosed after the newborn. Long-term follow-up after a diagnosis via NBS for Fabry 
disease includes follow-up visits with a geneticist and genetic counselor and with other 
specialists as needed (cardiology, nephrology, neurology, and gastroenterology) for the newborn, 
the newborn’s parent, and any other relatives that have been diagnosed 17. A diagnosis through 
NBS will get these family members access to treatment and evaluations with these specialists, 
 80 
which will reduce morbidities associated with Fabry disease and reduce the cost of treating these 
morbidities, like renal failure. But a concern with NBS for Fabry disease is the number of people 
who will be identified with late-onset variants, for which limited natural history information is 
known. For example, Missouri’s NBS program diagnosed multiple newborns with Fabry disease 
who have the A143T allele112,113. The Fabry population in Missouri’s genetics clinics has tripled 
in three years because of the number of diagnosed newborns and diagnosed relatives113. 61% of 
the clinics’ new patients have the A143T allele and in this population, there are few symptomatic 
adult patients113. Further research on the A143T allele indicates this allele is likely a benign 
variant or a disease-modifying variant114.  
While workforce availability issues are significant, an additional concern regarding long-
term follow-up is the question of whether the workforce and resources are being used 
appropriately to follow individuals who are diagnosed with Fabry disease through NBS. Many of 
the diagnosed newborns and their family members have late-onset variants99,100,102. Current 
guidelines provide limited information on how to monitor and manage asymptomatic newborns 
or asymptomatic individuals with late-onset variants17,18. In addition, research is still being 
conducted to determine if LysoGB3 is a reliable biomarker to track disease progression20,63. With 
the current guidelines and lack of a validated biomarker, a newborn with a late-onset variant 
would see the LSD clinic team every six months to a year to be monitored for disease 
progression17,144. Cost-benefit analyses have not been done to compare the costs of diagnosing 
and managing an asymptomatic newborn versus the costs of diagnosing someone after symptoms 
appear20.   
More evidence is needed to better assess when to start enzyme replacement therapy 
(ERT) for Fabry disease and the natural history of late-onset variants so that guidelines can be 
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updated20. The long-term follow-up component of the NBS system may aid in this process. 
According to the Advisory Committee on Heritable Disorders in Newborns and Children 
(ACHDNC), the federal committee that makes recommendations about NBS, the goals of NBS 
long-term follow-up include care coordination, evidence-based treatment, continuous quality 
improvement, and new knowledge discovery145,146. Long-term follow-up that is led by a NBS 
program will allow for uniform data collection to assess various aspects of these goals145. As 
with other conditions that were added to NBS and other population screenings, NBS for Fabry 
disease has identifed late-onset variants and variants of unknown significance that were 
previously unknown29,99,102. To achieve the goal of new knowledge discovery, additional data on 
these variants need to be collected. Federally-funded projects, like Inborn Errors of Metabolism 
Information System (IBEM-IS) and the Newborn Screening Translational Research Network’s 
Longitudinal Pediatric Data Resource (LPDR), are long-term data collection programs that will 
lead to a better understanding of Fabry disease’s natural history and how to treat it147,148. 
Participants in national and international programs are also researching how to utilize current 
NBS infrastructure and resources to collect this data for long-term follow-up70,149,150. 
Another concern with NBS for Fabry disease and other later-onset conditions is the 
continuity of access to and use of NBS results. The purpose of NBS has transformed slightly as 
NBS has started screening for late-onset conditions. With late-onset conditions like Fabry 
disease, diagnosed newborns are followed instead of being treated or managed soon after 
diagnosis. Although the purpose of NBS is not to identify individuals with later-onset conditions, 
once a newborn has been diagnosed via NBS with a later-onset condition, the NBS system or 
healthcare providers will need to ensure that the result will not be lost. This requirement raises 
the questions of whether NBS results will remain a part of the newborn’s medical records into 
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adulthood, whether parents will remember the diagnosis when their child starts showing 
symptoms, and whether parents will communicate the results to their child151. These questions 
surrounding NBS for Fabry disease are especially concerning for females because PCPs and 
other healthcare providers may not diagnose a female with Fabry disease. 
5.4 EDUCATION OF HEALTHCARE PROVIDERS 
Before screening for Fabry disease is implemented as part of the NBS system, it would be 
advantageous for Pennsylvania and other states to communicate with healthcare providers who 
will be involved in both short-term and long-term follow-up of newborns with positive screens 
and confirmed diagnoses. Primary care providers (PCPs) are often the ones who disclose positive 
newborn screen results to parents and several research studies indicate a need for more education 
for PCPs regarding NBS and Fabry disease. This education could include information about 
interpretation of NBS results in the context of Fabry disease, follow-up protocols for an 
abnormal screen, as well as general information about Fabry disease152–154. 
A few research studies have explored PCPs’ attitudes towards NBS and their knowledge 
of the conditions covered by NBS152–154. Most providers are in favor of NBS, even for later-onset 
conditions, and agree it is their responsibility to provide information and care to families with a 
positive newborn screen152,155. These studies reported gaps in providers’ knowledge of NBS, but 
providers shared the type of training and resources they would find helpful152,153,155. Providers 
displayed varying levels of comfort and knowledge with conditions on NBS panels and how to 
disclose results153–155. With cystic fibrosis and sickle cell disease, two of the more common 
conditions on NBS panels, there was significant misunderstanding among providers regarding 
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what different NBS results mean and the significance of being a carrier for sickle cell disease or 
cystic fibrosis155. Given these results and the complexities of Fabry disease being an X-linked 
condition that affects both males and females, it will be important to educate providers on what 
NBS results for Fabry disease mean and caution them that NBS does not detect 1/3 of females 
with Fabry disease61. 
Healthcare providers’ and NBS coordinators’ responses in these studies indicated ways 
healthcare providers can be given education and training about NBS in general and for specific 
conditions. Some PCPs thought it would be helpful to have training on how to give bad news153. 
With the addition of Fabry disease and other later-onset conditions to NBS, training on how to 
disclose results for different types of NBS conditions would be helpful. PCPs valued the 
information sheet sent with NBS results and wanted an information sheet to give parents at the 
results disclosure153. For condition-specific information, PCPs tended to search online for 
information and contacted specialty centers153. More online resources, such as the one currently 
being developed by a team from the Society for Inherited Metabolic Disorders, would enable 
PCPs to have easy access to information about Fabry disease and other NBS conditions to 
prepare for the initial results disclosure and for caring for the diagnosed child156. One research 
group suggested developing existing NBS online resources further, like STAR-G by the Western 
States Genetic Services Collaborative and NBS Connect by Emory University154.  
5.5 CONCLUSIONS 
The results from current NBS programs and pilot studies has shown that NBS for Fabry 
disease will increase the number of people diagnosed with Fabry disease across all age 
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groups102,113. The development of more online educational resources for healthcare providers 
about Fabry disease would benefit PCPs involved in the care of a diagnosed newborn and it 
would benefit healthcare providers involved in the care of family members diagnosed after the 
newborn. After they were diagnosed, some participants in this study shared that their healthcare 
providers were not familiar with Fabry disease, but some of their healthcare providers sought out 
resources and guidelines to educate themselves about the disease. The development of up-to-date 
resources for healthcare providers is especially important for diagnosis and treatment of at-risk 
females to ensure that healthcare providers understand that females can be affected and are not 
just carriers. 
 85 
APPENDIX A: IRB APPROVAL LETTER 
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APPENDIX B: PARTICIPANT INVITATION LETTER 
Dear Mr./Mrs. __________, 
I am writing on behalf of Kavitha Kolla, a genetic counseling intern at the University of 
Pittsburgh. Ms. Kolla is conducting a research study at the Children’s Hospital of Pittsburgh to 
learn more about patient and family knowledge and thoughts about newborn screening for Fabry 
disease.  
For this study, Ms. Kolla will be interviewing both parents of children who have Fabry 
disease and adults who have Fabry disease to learn more about their experiences with Fabry 
disease and to learn about their attitudes about newborn screening for Fabry disease.  
I invite you to consider participating in an audio recorded one-on-one interview with Ms. 
Kolla. Participation is completely voluntary. Your decision to participate will not affect your 
medical care or your child’s medical care at any UPMC facility. Your identity and responses will 
be kept confidential. 
The interview would last about an hour, either over the phone or in person at Children’s 
Hospital of Pittsburgh or Montefiore Hospital. Questions will focus on various aspects of 
newborn screening for Fabry disease. During the interview, you only have to share as much 
information as you feel comfortable sharing.  
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If you have any questions about participating in the study or would like to learn more 
about how to participate, please fill out the attached response card with your contact information 
and one of our study staff will contact you. 
 
Sincerely, 
Genetic Counselor 
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APPENDIX C: PARTICIPANT VERBAL CONSENT SCRIPT (TELEPHONE) 
Hello, my name is Kavitha Kolla and I’m a genetic counseling intern from Children’s 
Hospital of Pittsburgh. I’m working on a study called “Knowledge and Attitudes about Newborn 
Screening for Fabry Disease”. The genetic counselor from the Lysosomal Storage Disorders 
Clinic at Children’s Hospital of Pittsburgh referred you to this study by letter and you expressed 
interest in hearing more about it. Is now a good time for a brief introduction? 
 
You are being asked to participate in this research study because you or your child, or 
both, have been diagnosed with Fabry disease. The purpose of this research study is to better 
understand the experiences of parents of children who have Fabry disease and adults who have 
Fabry disease and to learn what they think of newborn screening for Fabry disease. To 
accomplish this, we will be interviewing parents of children who have Fabry disease and adults 
who have Fabry disease.  
 
Participants are asked to complete a telephone or in person interview with me, the main 
investigator in the study, which last about one hour. In person interviews can take place at either 
Children’s Hospital of Pittsburgh or Montefiore Hospital, if you receive enzyme replacement 
therapy infusions at Montefiore Hospital. The interview will explore your experiences with 
Fabry disease, the timing of the diagnosis, and your thoughts on newborn screening for Fabry 
disease. Interviews will be audio recorded, typed, and evaluated. Identifying information, such as 
your name or your child’s name, will be removed from the typed document. A member of the 
study team might contact you after you complete your interview for a follow-up interview to 
explore new topics raised by later interviewees.   
 
All responses to the interview are confidential and responses will be stored in a secure 
manner. Personal password-protected computers and a locked file cabinet will be used to store 
records at Children’s Hospital of Pittsburgh. Per University of Pittsburgh policy, all research 
records for this study will be stored for at least 7 years without information that can be linked to 
participants’ identities. It is possible that in the future, other investigators interested in 
performing similar research will request access to data or materials from this study. If data is 
shared with other investigators, they will not be able to link the data to the participants’ identities 
in any way. 
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Your participation may not directly benefit you, but information gathered through this 
study may be shared with state personnel who may consider adding newborn screening for Fabry 
disease to the newborn screening panel. This knowledge will help healthcare professionals 
provide better support and education during the newborn screening process. 
 
There is minimal risk to participating in this study since there is no blood draw or other 
medical procedures. Some of the interview questions may cause some distress because they will 
ask about your experiences with Fabry disease and thinking about how an earlier diagnosis 
would have impacted you and your family. During the interview, you only have to answer 
questions you are comfortable answering and share as much as you want. 
 
Your participation is voluntary and you may withdraw from this project at any time. Any 
answers recorded in the interview prior to withdrawal will remain a part of the study. Your 
decision to participate or not to participate will not affect your current or future health care at any 
of the University of Pittsburgh Medical Center facilities. 
 
In unusual cases, in response to a court order, the investigators may be required to release 
identifiable research study information (which may include your identifiable medical 
information) related to your participation in this research study. If investigators learn that you or 
someone with whom you are involved is in serious danger or potential harm, they will need to 
inform the appropriate agencies, as required by Pennsylvania law. No medical procedures will be 
performed in this study, but if you believe that the research procedures have resulted in injury to 
you, contact the Principal Investigator immediately. Emergency medical treatment for injuries 
solely and directly related to your participation in this research study will be provided to you by 
the hospitals of UPMC. Your insurance provider may be billed for the costs of this emergency 
treatment, but none of those costs will be charged directly to you. If your research-related injury 
requires medical care beyond this emergency treatment, you will be responsible for the costs of 
this follow-up care. There is no plan for any direct additional financial compensation for 
participation in this study. 
 
You are encouraged to ask questions and voice concerns or complaints about any aspects 
of this research study during the course of this study and in the future. Questions and concerns 
will be addressed by a qualified individual, the Principal Investigator, Kavitha Kolla at ______, 
or the co-investigator Catherine Walsh Vockley at ______. You may contact the Human Subjects 
Protection Advocate of the IRB office at the University of Pittsburgh (1-866-212-2668) to 
discuss problems, concerns, and questions; obtain information; offer input; or discuss situations 
in the event that the research team is unavailable. 
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Do you have any questions about the study or the information I just went over? 
 
Are you interested in participating in this study? 
 
If yes, can we arrange a time for the interview now, or do you want me to re-contact you 
at a specific time in the future to do that? 
 
 
 91 
APPENDIX D: PARTICIPANT INTERVIEW GUIDE 
Introduction to research project (review information from verbal consent that was previously 
obtained) 
 
Getting to know participant 
To begin, could you tell me a little bit about yourself and your family? 
  
What have your experiences with Fabry disease been like?  
 Follow-up questions to consider asking for experience with Fabry disease: 
 
Tell me about some of your earliest experiences with Fabry disease. 
 
How were you/your child diagnosed with Fabry disease?  
 
What symptoms or features started the path to diagnosis? Did the family medical history play a 
role in your/your child’s diagnosis?  
(if yes, family history did play a role) Were you/your child tested for Fabry based only on the 
family history? 
 
How old were you when you were diagnosed with Fabry disease? or 
  How old was your child when he/she was diagnosed with Fabry disease? 
 
How many doctors and specialists did you see between the time symptoms started and when 
you/your child was diagnosed? Who was responsible for the diagnosis being confirmed? 
 
How much time was there between when the symptoms started and when you/your child was 
diagnosed with Fabry disease? 
 
Do you think your primary care provider understood the diagnosis? 
Did your specialists/specialty care team provide written materials for you and/or for your PCP to 
learn more about Fabry? 
What other resources did you use to understand Fabry? 
 
Impact 
 How has the diagnosis impacted you/your child? 
   
How has the diagnosis impacted your family? 
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Have any other family members been diagnosed since you/your child were diagnosed? 
 
 Have you/your child started enzyme replacement therapy? If yes, at what age? 
 
The treatment for Fabry disease, enzyme replacement therapy, is started after symptoms appear. 
How would you feel if you or your child was diagnosed with Fabry disease before symptoms 
appear? 
 
Imagine that you have a child who is diagnosed with Fabry disease before symptoms appear and 
before treatment is needed. How might this affect the way you raise your child?   
 
Previous knowledge about newborn screening 
 What have you heard about newborn screening before participating in this study? 
  
What do you believe is the purpose of newborn screening? 
 
Do you know when newborn screening is done?  
 
What kinds of conditions do you think newborn screening looks for? 
  
What do you think are some reasons why a condition would be included on newborn screening? 
 
Based on those reasons, what is your opinion on Fabry disease being a part of newborn 
screening?  
 
Educate about newborn screening. Explain how newborn screening for Fabry works. 
 Educational piece (separate document). Walk through educational piece together 
 
Opinions on newborn screening and hypothetical questions 
The advisory committee that reviews conditions to be added to newborn screening usually 
includes conditions that start in infancy and have a treatment. What is your opinion on conditions 
being included in newborn screening that start later, for example, in childhood or adolescence? 
 
The original purpose of newborn screening is to identify infants at immediate risk of developing 
life-threatening symptoms associated with a serious condition. Do you think Fabry disease meets 
this definition of urgency? 
 
Newborn screening results can come back positive (which means a higher risk for a specific 
condition), negative, or unclear. 
 
Imagine that your newborn child has a positive screen for Fabry disease on newborn screening. 
A positive screen is followed by a diagnostic test. The diagnostic test for Fabry disease shows 
that your child has Fabry disease. How would you feel about your newborn child receiving a 
diagnosis of Fabry disease?  
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After a positive screen, the diagnostic test for Fabry disease shows that your child does not have 
Fabry disease. This is known as a false positive result. How would you feel about your newborn 
child receiving a positive screen followed by a negative diagnostic test? 
 
One possible result on newborn screening is a negative result, which means the baby is not at 
increased risk of having Fabry disease. How would you feel about your newborn child receiving 
a negative screen for Fabry disease? 
 
Another possible result on newborn screening is unclear results, which means we do not know if 
the baby is at increased risk or not for Fabry disease. How would you feel about unclear test 
results for your newborn child? 
 
In most states, parents can opt out of newborn screening, but parents are encouraged not to opt 
out because of the critical health implications for their child if he or she tests positive. 
Should parents be given the option to opt out of testing for Fabry and other later onset conditions 
on newborn screening?  
What sort of information do you think parents should be given about these conditions before 
making their decision? 
Do you think parents should know that if their child has one of these conditions and they do not 
pursue newborn screening for Fabry and other later onset conditions on newborn screening, it 
may take multiple doctors or multiple years to be diagnosed? 
 
How would a diagnosis at birth through newborn screening have impacted you/your child? Your 
family? 
 
What sort of counseling and support did you receive at the time of your/your child’s diagnosis? 
  What sort of counseling and support should go along with a diagnosis at birth? 
 
After a positive screen, who would you want to talk to for more information and support?  
Would you want to talk to a genetic counselor? Would you want to talk to a physician/specialist? 
Or both? 
 What other forms of support or resources would you want after a positive screen? 
 
In summary, do you think NBS should be done for Fabry? Why or why not?  
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